[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1008
1. Sales KJ, Grant V, Jabbour HN: Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element. Mol Cell Endocrinol; 2008 Mar 26;285(1-2):51-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In endometrial adenocarcinomas COX-2 and F-series prostanoid (FP) receptor expression and prostanoid biosynthesis (PGE(2) and PGF(2alpha)) are elevated.
  • In the present study, we investigated the effect of PGE(2) and PGF(2alpha) on the expression of COX-2 via the FP receptor in endometrial adenocarcinoma cells stably expressing the FP receptor (FPS cells).
  • These data indicate that PGE(2) and PGF(2alpha) biosynthesized locally within endometrial adenocarcinomas can regulate tumor cell function in an autocrine/paracrine manner via the FP receptor.
  • [MeSH-minor] Adenocarcinoma / metabolism. Cell Line, Tumor. Endometrial Neoplasms / metabolism. Enzyme Activation. Enzyme Inhibitors / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Genes, Reporter. Humans. Inositol 1,4,5-Trisphosphate / metabolism. Promoter Regions, Genetic. Prostaglandin Antagonists / metabolism. Receptors, Prostaglandin / antagonists & inhibitors. Receptors, Prostaglandin / genetics. Receptors, Prostaglandin / metabolism. Receptors, Prostaglandin E / metabolism. Xanthones / metabolism

  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49954-64 [14517215.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] Mol Endocrinol. 2004 Jun;18(6):1533-45 [15044590.001]
  • [Cites] Trends Endocrinol Metab. 2004 Oct;15(8):398-404 [15380812.001]
  • [Cites] Am J Obstet Gynecol. 1978 Mar 15;130(6):640-6 [637076.001]
  • [Cites] Br J Obstet Gynaecol. 1981 Apr;88(4):434-42 [7225303.001]
  • [Cites] Br J Obstet Gynaecol. 1983 Dec;90(12):1135-40 [6580910.001]
  • [Cites] Br J Obstet Gynaecol. 1984 Jul;91(7):673-80 [6589016.001]
  • [Cites] Br J Obstet Gynaecol. 1988 Feb;95(2):162-5 [2894838.001]
  • [Cites] J Pharmacol Exp Ther. 1990 Nov;255(2):756-68 [2147038.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2522-30 [11980644.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31 [12242329.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12151-6 [12566441.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35451-7 [12824187.001]
  • [Cites] Life Sci. 2003 Dec 5;74(2-3):143-53 [14607241.001]
  • [Cites] Reproduction. 2003 Nov;126(5):559-67 [14611628.001]
  • [Cites] J Biol Chem. 1991 Aug 25;266(24):15771-81 [1874734.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2712-8 [8381413.001]
  • [Cites] Prostaglandins. 1993 May;45(5):413-26 [8321911.001]
  • [Cites] J Biol Chem. 1994 Jul 1;269(26):17619-25 [8021271.001]
  • [Cites] Mol Pharmacol. 1994 Sep;46(3):477-84 [7935328.001]
  • [Cites] J Biol Chem. 1995 Nov 17;270(46):27489-94 [7499206.001]
  • [Cites] Biochem Pharmacol. 1995 Nov 9;50(10):1731-3 [7503778.001]
  • [Cites] Biol Chem Hoppe Seyler. 1996 Jun;377(6):373-84 [8839983.001]
  • [Cites] Gastroenterol Clin North Am. 1996 Dec;25(4):773-91 [8960892.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):455-60 [9521170.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3914-9 [9520467.001]
  • [Cites] J Biol Chem. 1998 Apr 10;273(15):8890-6 [9535870.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Int J Tissue React. 1998;20(1):3-15 [9561441.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):22903-6 [10438452.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84 [10454504.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1193-226 [10508233.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6112-8 [15579767.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4657-64 [16081631.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1697-705 [16373414.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1391-9 [16614756.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14507-12 [16973753.001]
  • [Cites] Curr Opin Investig Drugs. 2007 May;8(5):411-5 [17520870.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93 [10634944.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):543-50 [10753183.001]
  • [Cites] Cancer Lett. 2000 Aug 1;156(1):57-61 [10840160.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] Urology. 2000 Oct 1;56(4):671-6 [11018637.001]
  • [Cites] Trends Endocrinol Metab. 2000 Apr;11(3):91-9 [10707049.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2243-9 [11344234.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):28-32 [11782353.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):424-32 [11809691.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • (PMID = 18316157.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01/2(61014)
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / AL 8810; 0 / Enzyme Inhibitors; 0 / Prostaglandin Antagonists; 0 / Receptors, Prostaglandin; 0 / Receptors, Prostaglandin E; 0 / Xanthones; 0 / prostaglandin F2alpha receptor; 33458-93-4 / 6-isopropoxy-9-oxoxanthene-2-carboxylic acid; 85166-31-0 / Inositol 1,4,5-Trisphosphate; B7IN85G1HY / Dinoprost; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2694994; NLM/ UKMS2447
  •  go-up   go-down


2. Barker LC, Brand IR, Crawford SM: Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin; 2009 May;25(5):1105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
  • OBJECTIVE: To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment.
  • MAIN OUTCOME MEASURE: Resolution of endometrial thickening measured by transvaginal ultrasound at 3-month intervals; the response of metastases was assessed by standard oncological criteria.
  • During treatment with AIs, mean endometrial thickness in the eight patients with EH decreased progressively by 81.7% from 14.7 mm at the start of treatment to 2.7 mm following 36 months of treatment.
  • A greater original mean endometrial thickness of 17 mm was seen in the four patients with localised EA, this fell progressively by 67.1% to 5.6 mm following 36 months of treatment.
  • CONCLUSION: Our results indicate that treatment of EH with anastrozole or letrozole can reduce endometrial thickness as seen ultrasonically, and that in some cases AI treatment can reduce endometrial thickness in patients with localised EA.
  • [MeSH-major] Aromatase Inhibitors / pharmacology. Carcinoma / drug therapy. Endometrial Hyperplasia / drug therapy. Endometrial Neoplasms / drug therapy. Endometrium / drug effects. Nitriles / pharmacology. Triazoles / pharmacology

  • Hazardous Substances Data Bank. LETROZOLE .
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19301987.001).
  • [ISSN] 1473-4877
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; 7LKK855W8I / letrozole
  •  go-up   go-down


3. van der Horst C, Evans AJ: Peritoneal keratin granulomas complicating endometrial carcinoma: a report of two cases and review of the literature. Int J Gynecol Cancer; 2008 May-Jun;18(3):549-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal keratin granulomas complicating endometrial carcinoma: a report of two cases and review of the literature.
  • Squamous differentiation in endometrial adenocarcinoma is common.
  • Keratin granulomas accompanied by viable adenocarcinoma cells are regarded as conventional metastatic foci.
  • However, the significance of keratin granulomas without accompanying viable adenocarcinoma cells is difficult to ascertain.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Granuloma / pathology. Keratins / metabolism. Peritoneal Diseases / pathology

  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645505.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


Advertisement
4. Carlsson J, Helenius G, Karlsson M, Klinga-Levan K: Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma. Cancer Cell Int; 2010 Nov 24;10:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma.
  • In a previous microarray study performed by our group, Gpx3 was identified as a potential biomarker for rat endometrial adenocarcinoma (EAC), since the expression was highly downregulated in rat EAC tumors.
  • In addition we have examined the expression of GPX3 and MET in 30 human EACs of different FIGO grades and 20 benign endometrial tissues.
  • Preliminary results also suggest that the production of H2O2 is higher in rat endometrial tumors with down-regulated Gpx3 expression.
  • A likely consequence of loss of GPX3 protein function would be a higher amount of ROS in the cancer cell environment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Neonate. 1990;57(6):343-8 [2164849.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):85-94 [18175071.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]
  • [Cites] Z Versuchstierkd. 1987;30(5-6):209-16 [3445711.001]
  • [Cites] Cancer Cell Int. 2009;9:12 [19426485.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11715-20 [9751731.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1472-81 [17245700.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14):2343-50 [10327054.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2081-8 [17332337.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jun;127(2):118-27 [11425450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4731-5 [8197126.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1245-51 [3473261.001]
  • [Cites] Curr Probl Cancer. 1997 Mar-Apr;21(2):65-127 [9128804.001]
  • [Cites] Science. 1991 Feb 15;251(4995):802-4 [1846706.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8043-50 [17804715.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1023-34 [11381087.001]
  • [Cites] Oncol Rep. 2008 Dec;20(6):1299-303 [19020706.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1282-93 [19195878.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Int J Oncol. 2010 Feb;36(2):405-14 [20043075.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:228-32 [9474874.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6 [9012848.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):23-42 [12653669.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4742-9 [16651427.001]
  • (PMID = 21106063.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3014921
  •  go-up   go-down


5. Zhu LC, Yim J, Chiriboga L, Cassai ND, Sidhu GS, Moreira AL: DC-LAMP stains pulmonary adenocarcinoma with bronchiolar Clara cell differentiation. Hum Pathol; 2007 Feb;38(2):260-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DC-LAMP stains pulmonary adenocarcinoma with bronchiolar Clara cell differentiation.
  • DC-LAMP marks pulmonary adenocarcinomas that show Clara cell characteristics by electron microscopy.
  • DC-LAMP staining was lost in solid type adenocarcinomas but persisted in well-differentiated areas.
  • DC-LAMP and CC-10 reactivity was also observed in endometrial adenocarcinomas but not in other tumor types.
  • [MeSH-major] Adenocarcinoma / pathology. Bronchi / pathology. Lung Neoplasms / pathology. Lysosome-Associated Membrane Glycoproteins / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Lung / chemistry. Lung / pathology. Lung / ultrastructure. Male. Microscopy, Electron. Middle Aged. Nuclear Proteins / analysis. Prognosis. Pulmonary Surfactants / analysis. Survival Rate. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056097.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Lysosome-Associated Membrane Glycoproteins; 0 / Nuclear Proteins; 0 / Pulmonary Surfactants; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


6. Hu K, Zhong G, He F: Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer; 2005 May-Jun;15(3):537-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma.
  • We assessed the expression of estrogen receptors (ER)alpha and ERbeta in 114 human endometrial hyperplasia and adenocarcinomas.
  • The aim of this study was to determine the expression of both ER isoforms in human endometrial tissue by immunohistochemistry.
  • In atypia hyperplasia and adenocarcinoma, both ERalpha and ERbeta were decreased significantly (P < 0.05).
  • Most endometrial adenocarcinomas expressed ERalpha, either alone or in combination with ERbeta, and the ERbeta/ERalpha ratio was decreased when compared to normal proliferation (P < 0.05).
  • Also, we found that the expression of ERalpha and ERbeta has no relationship with the status of lymph node of adenocarcinoma (P > 0.05).
  • Both ERalpha and ERbeta play an important role in endometrial hyperplasia and carcinomas, the levels of ERalpha and ERbeta appear be used as prognostic indicators.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Endometrial Hyperplasia / genetics. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Estrogen Receptor alpha / biosynthesis. Estrogen Receptor beta / biosynthesis. Gene Expression Profiling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882182.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Protein Isoforms
  •  go-up   go-down


7. Liao CL, Lee MY, Tyan YS, Kok LF, Wu TS, Koo CL, Wang PH, Chao KC, Han CP: Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. J Transl Med; 2009;7:37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
  • OBJECTIVE: Endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) are uterine malignancies that have differing biological behaviors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Endometrial Neoplasms / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Uterine Cervical Neoplasms / metabolism. Vimentin / metabolism
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry. Sensitivity and Specificity. Tissue Array Analysis


8. Srikantia N, B R, A G R, Kalyan SN: Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases. Indian J Med Paediatr Oncol; 2009 Apr;30(2):80-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases.
  • Endometrial adenocarcinoma is the third common malignancy of the female genital tract occurring most often in the postmenopausal age group.
  • We present an unusual case of endometrial adenocarcinoma in a premenopausal woman with simultaneous metastases in brain, liver, skin and skeletal system, within one month of completion of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):530-3 [9190989.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):281-4 [12068176.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):524-8 [15099973.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Aug;4(4):679-89 [15270671.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):333-9 [15297170.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Sep;35(9):1488-94 [18799902.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1715-20 [19443392.001]
  • (PMID = 20596308.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2885881
  • [Keywords] NOTNLM ; Adjuvant chemotherapy / endometrial carcinoma / multiple organ metastases
  •  go-up   go-down


9. Walrath JD, Lelli GJ Jr, Engelbert M, Kazim M: Metastatic endometrial carcinoma resulting in orbital apex compression. Ophthal Plast Reconstr Surg; 2007 May-Jun;23(3):250-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic endometrial carcinoma resulting in orbital apex compression.
  • A 63-year-old woman presented subacutely with signs of orbital apex and cavernous sinus disease in the setting of widespread, untreated metastatic carcinoma of the uterus.
  • The underlying diagnosis was confirmed with repeat endometrial biopsy, revealing well-differentiated endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Nerve Compression Syndromes / etiology. Optic Nerve Diseases / etiology. Orbital Neoplasms / secondary. Paranasal Sinus Diseases / etiology

  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519676.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Hoekstra AV, Kim JJ, Keh P, Schink JC: Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report. J Reprod Med; 2008 Nov;53(11):869-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report.
  • BACKGROUND: Fertility-sparing treatment may be offered as an alternative to standard surgical management of early-stage, well-differentiated endometrial cancer in young women.
  • CASE: We describe a 29-year-old woman who used oral contraceptive pills on a long-term basis in whom early-stage, well-differentiated endometrial cancer was diagnosed.
  • CONCLUSION: Combination oral contraceptive pills may stimulate clonal expansion of endometrial cells that lack PR, leading to endometrial adenocarcinoma unresponsive to progestin therapy.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MEGESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097521.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA127674-02; United States / NCI NIH HHS / CA / R21 CA127674; United States / NCI NIH HHS / CA / R21 CA127674-02
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Contraceptives, Oral, Hormonal; 0 / Progesterone Congeners; 0 / Receptors, Progesterone; EA6LD1M70M / Megestrol
  • [Other-IDs] NLM/ NIHMS282703; NLM/ PMC4780569
  •  go-up   go-down


11. Castilho MS, Jacinto AA, Viani GA, Campana A, Carvalho J, Ferrigno R, Novaes PE, Fogaroli RC, Salvajoli JV: Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney. Radiat Oncol; 2006;1:44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney.
  • BACKGROUND: Pelvic Radiotherapy (RT) as a postoperative treatment for endometrial cancer improves local regional control.
  • CASE: We report on a 50 year-old patient with a serous-papiliferous adenocarcinoma of the uterus who was submitted to surgical treatment without lymph node sampling followed by Brachytherapy, and Chemotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Radiotherapy, Intensity-Modulated / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2000 Sep 15;70(5):844-6 [11003368.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1004-9 [14575831.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):376-9 [14751190.001]
  • [Cites] J Urol. 1980 May;123(5):766-7 [7420573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):977-83 [1976615.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):174-6 [7901069.001]
  • [Cites] Transplantation. 1994 Aug 27;58(4):520-2 [8073523.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):151-5 [7557603.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):57-60 [8841468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):11-7 [16024116.001]
  • (PMID = 17116263.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1660561
  • [General-notes] NLM/ Original DateCompleted: 20070809
  •  go-up   go-down


12. Desrosiers L, Fadare O, Xiao ZF, Dresser K, Wang SA: Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium. Ann Diagn Pathol; 2008 Apr;12(2):112-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium.
  • This study was conducted to determine whether, in a pure population of patients with International Federation of Gynecology and Obstetrics stage I endometrioid endometrial (S1EE) carcinoma that is confined to the uterus and without lymph node metastases, the presence of lymphovascular space invasion (LVSI) is positively associated with vaginal relapses.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325471.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. van de Poll-Franse LV, Mols F, Essink-Bot ML, Haartsen JE, Vingerhoets AJ, Lybeert ML, van den Berg HA, Coebergh JW: Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study. Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):125-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study.
  • PURPOSE: To compare the health-related quality of life (HRQOL) among 5-10-year survivors of Stage I-II endometrial (adeno-)carcinoma (EC) treated with surgery alone or surgery with external beam adjuvant radiotherapy (EBRT) and an age-matched norm population.
  • METHODS AND MATERIALS: A population-based, cross-sectional survey was conducted by the Eindhoven Cancer Registry.
  • Information from the questionnaires returned was linked to data from the Eindhoven Cancer Registry on patient, tumor, and treatment characteristics.
  • The analyses were restricted to women with Stage I-II disease at diagnosis, treated with either surgery alone or surgery with adjuvant EBRT, and without recurrent disease or new primary malignancies (n = 264).
  • The patients who had received adjuvant EBRT (n = 80) had had a significantly higher tumor stage and grade at diagnosis (p < 0.0001) and a longer mean time since diagnosis (p = 0.04).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy. Health Status. Quality of Life

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17544600.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Geisler JP, Linnemeier GC, Manahan KJ: Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium. Int J Gynaecol Obstet; 2007 Jul;98(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium.
  • BACKGROUND: The purpose is to determine the rate of lymph node metastases in women with endometrioid adenocarcinoma of the endometrium (EAE) undergoing systematic lymphadenectomy.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Lymph Node Excision. Lymphatic Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490668.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Shield PW, Koivurinne K: The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Cytopathology; 2008 Aug;19(4):218-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the value of calretinin and cytokeratin (CK) 5/6 in discriminating mesothelioma from adenocarcinoma in serous effusion specimens.
  • METHODS: A total of 101 recent, histologically or clinically confirmed malignant effusions with immunostained cell block preparations were reviewed.
  • The cases consisted of 34 mesotheliomas and 67 adenocarcinomas.
  • The adenocarcinomas included metastatic carcinomas from the breast (12), lung (19), stomach (3), colon (1), pancreas (2), ovary (6) endometrium (1) and 23 histologically confirmed metastases from unknown primary sites.
  • Only 3% (2/67) of adenocarcinomas were positive for calretinin, one being a lung adenocarcinoma and the other an adenocarcinoma of unknown primary site in an ascitic fluid.
  • Six (9%) adenocarcinomas were positive, including metastases from the lung (1), breast (1), ovary (2) and unknown primary site (2).
  • Four of the six adenocarcinoma cases positive for CK5/6 were in ascitic fluids.
  • Only one adenocarcinoma case, (which was from unknown primary site in an ascitic fluid sample), was positive for both markers.
  • CK5/6 staining may be less useful for peritoneal fluid specimens where metastatic adenocarcinomas may be more likely to express the antigen.
  • The two markers make a useful addition to EMA and the panel of adenocarcinoma markers routinely applied to effusion specimens.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Keratin-5 / analysis. Keratin-6 / analysis. Mesothelioma / diagnosis. Neoplasms / diagnosis. S100 Calcium Binding Protein G / analysis
  • [MeSH-minor] Calbindin 2. Diagnosis, Differential. Humans. Pleural Effusion / pathology. Reproducibility of Results. Sensitivity and Specificity. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916095.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Keratin-5; 0 / Keratin-6; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


16. Sadeghi H, Taylor HS: HOXA10 regulates endometrial GABAA {pi} receptor expression and membrane translocation. Am J Physiol Endocrinol Metab; 2010 Apr;298(4):E889-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXA10 regulates endometrial GABAA {pi} receptor expression and membrane translocation.
  • Expression of the GABA(A) pi receptor has been described previously in the human endometrium in both luminal epithelium and stroma.
  • Its expression is increased during decidualization in rodents and in the implantation window of human endometrium.
  • Here we localized GABA pi subunit receptor protein in human endometrium and identified regulators of gene expression and activation.
  • GABA(A) pi was localized to the cell surface, and expression increased during the window of embryo implantation in human endometrium.
  • The well-differentiated human endometrial adenocarcinoma cell line Ishikawa was treated with progesterone and transfected with pcDNA-HOXA10, HOXA10 siRNA, or respective controls.
  • Modification of subtype composition and translocation of the GABA receptor ion channel likely modulate endometrial receptivity.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):661-6 [8476779.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Dec;43(7):635-40 [1472455.001]
  • [Cites] Nature. 1995 Mar 30;374(6521):460-3 [7700356.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):57-9 [7542903.001]
  • [Cites] Development. 1996 Sep;122(9):2687-96 [8787743.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):136-42 [8989247.001]
  • [Cites] J Steroid Biochem Mol Biol. 1996 Sep;59(1):31-9 [9009235.001]
  • [Cites] J Biol Chem. 1997 Jun 13;272(24):15346-50 [9182563.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 1997 May;19(4):215-22 [9228646.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1379-84 [9525980.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):1129-35 [10084606.001]
  • [Cites] Hum Reprod. 1999 May;14(5):1328-31 [10325287.001]
  • [Cites] Mol Pharmacol. 1999 Sep;56(3):598-610 [10462548.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):522-8 [15494461.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1034:1-18 [15731295.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):331-55 [16632680.001]
  • [Cites] Eur Neuropsychopharmacol. 2007 Jan 15;17(2):108-15 [16574382.001]
  • [Cites] Fertil Steril. 2006 Dec;86(6):1750-7 [17074347.001]
  • [Cites] FASEB J. 2007 Mar;21(3):885-95 [17197387.001]
  • [Cites] Curr Med Chem. 2007;14(25):2680-701 [17979718.001]
  • [Cites] Reprod Sci. 2008 May;15(5):529-35 [18579861.001]
  • [Cites] Mol Hum Reprod. 2008 Oct;14(10):613-8 [18829447.001]
  • [Cites] Curr Med Chem. 2009;16(4):455-72 [19199916.001]
  • [Cites] Br J Pharmacol. 2009 Mar;156(6):869-84 [19298394.001]
  • [Cites] Fertil Steril. 2010 Apr;93(6):2027-34 [18555231.001]
  • [Cites] Front Neuroendocrinol. 2000 Jan;21(1):1-56 [10662535.001]
  • [Cites] Mol Pharmacol. 2000 Jun;57(6):1262-70 [10825399.001]
  • [Cites] Gene Ther. 2000 Aug;7(16):1378-84 [10981664.001]
  • [Cites] Endocrinology. 2001 May;142(5):1770-7 [11316740.001]
  • [Cites] Brain Res Brain Res Rev. 2001 Nov;37(1-3):81-90 [11744076.001]
  • [Cites] Mol Endocrinol. 2002 Mar;16(3):571-9 [11875117.001]
  • [Cites] Endocrinology. 2002 Jun;143(6):2119-38 [12021176.001]
  • [Cites] Fertil Steril. 2002 Sep;78(3):577-80 [12215336.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):1-13 [12482956.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):238-43 [12519859.001]
  • [Cites] Fertil Steril. 2003 Nov;80(5):1169-74 [14607569.001]
  • [Cites] Neurosci Lett. 1982 Dec 13;33(3):275-9 [6298666.001]
  • [Cites] Neurosci Lett. 1983 Dec 2;42(2):155-60 [6664627.001]
  • [Cites] J Neurochem. 1984 Jul;43(1):120-5 [6726240.001]
  • [Cites] J Neurochem. 1986 Jan;46(1):166-72 [3940278.001]
  • [Cites] Gynecol Obstet Invest. 1985;20(4):199-203 [3002921.001]
  • [Cites] Eur J Pharmacol. 1990 Jun 12;188(6):403-6 [2164942.001]
  • [Cites] Endocrinology. 1990 Dec;127(6):2757-62 [2249627.001]
  • [Cites] Cell. 1992 Jan 24;68(2):283-302 [1346368.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Apr;42(2):201-10 [1373641.001]
  • [Cites] J Psychiatry Neurosci. 1994 Jan;19(1):24-9 [8148363.001]
  • (PMID = 20103740.001).
  • [ISSN] 1522-1555
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD-0388679; United States / NICHD NIH HHS / HD / U54-HD-052668
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GABRP protein, human; 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / Receptors, GABA-A; 140441-81-2 / HOXA10 protein, human; 4G7DS2Q64Y / Progesterone
  • [Other-IDs] NLM/ PMC3774337
  •  go-up   go-down


17. Hori M, Kim T, Murakami T, Imaoka I, Onishi H, Nakamoto A, Nakaya Y, Tomoda K, Tsutsui T, Enomoto T, Kimura T, Nakamura H: MR imaging of endometrial carcinoma for preoperative staging at 3.0 T: comparison with imaging at 1.5 T. J Magn Reson Imaging; 2009 Sep;30(3):621-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of endometrial carcinoma for preoperative staging at 3.0 T: comparison with imaging at 1.5 T.
  • PURPOSE: To prospectively compare magnetic resonance imaging (MRI) at 3.0 T and 1.5 T in the same patients for preoperative evaluation of endometrial carcinoma.
  • MATERIALS AND METHODS: Thirty consecutive patients with endometrial carcinoma underwent MRI at both 3.0 T and 1.5 T as well as surgery.
  • CONCLUSION: 3.0 T MRI is an equivalent imaging modality to 1.5 T imaging for presurgical evaluation of endometrial carcinoma, although not significantly superior to 1.5 T imaging.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Endometrial Neoplasms / pathology. Magnetic Resonance Imaging / methods. Preoperative Care / methods
  • [MeSH-minor] Adult. Aged. Area Under Curve. Artifacts. Contrast Media. Endometrium / pathology. Endometrium / surgery. Female. Gadolinium. Heterocyclic Compounds. Humans. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Magnetics. Middle Aged. Neoplasm Staging. Observer Variation. Organometallic Compounds. Prospective Studies. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711413.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Heterocyclic Compounds; 0 / Organometallic Compounds; 0199MV609F / gadoteridol; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


18. Vanhoecke BW, Bracke ME, Kloosterboer HJ, Depypere HT: Tibolone and its metabolites inhibit invasion of human mammary carcinoma cells in vitro. Maturitas; 2006 Jun 20;54(3):229-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tibolone and its metabolites inhibit invasion of human mammary carcinoma cells in vitro.
  • Tibolone is used in postmenopausal women to alleviate menopausal symptoms and to prevent osteoporosis, but it does not stimulate the endometrium and the breast.
  • Up to date, little data are available on the effect of tibolone on breast cancer initiation and progression.
  • OBJECTIVE: In the present in vitro study, we investigated the effect of tibolone and its metabolites (3alpha-OH tibolone, 3beta-OH tibolone, the Delta4 isomer and the sulphated isoform) on invasion of human breast cancer cells.
  • In an attempt to probe the mechanism underlying the anti-invasive effect, we found that pro-MMP-9 release was markedly reduced in the supernatant of MCF-7/6 breast cancer cells treated with tibolone, 3alpha-OH tibolone and the Delta4 isomer but, interestingly, not with the sulphated metabolite.
  • CONCLUSION: We conclude that tibolone and its 3beta-OH metabolite have an anti-invasive effect on the tested breast cancer cell lines in vitro.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Cell Proliferation / drug effects. Estrogen Receptor Modulators / pharmacology. Norpregnenes / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16581209.001).
  • [ISSN] 0378-5122
  • [Journal-full-title] Maturitas
  • [ISO-abbreviation] Maturitas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Estrogen Receptor Modulators; 0 / Norpregnenes; EC 3.4.24.35 / Matrix Metalloproteinase 9; FF9X0205V2 / tibolone
  •  go-up   go-down


19. Zergeroğlu S, Ozdemir HB, Ozel M, Kuzey GM, Mollamahmutoğlu L: The prognostic importance of proliferative activity and oestrogen receptor expression in stage I endometrial carcinomas. J Obstet Gynaecol; 2006 Nov;26(8):798-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic importance of proliferative activity and oestrogen receptor expression in stage I endometrial carcinomas.
  • The purpose of this study was to evaluate the prognostic significance of steroid hormone receptor proliferation index in endometrial adenocarcinoma.
  • In this study, the correlation between oestrogen receptor expression, proliferation index and FIGO grade, age, myometrial invasion, tumour size and menopause status was evaluated in 40 patients with endometrial carcinoma.
  • Quantitative assessment of tumour proliferation and expression of oestrogen receptor were found to be important prognostic indicators in endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17130035.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen
  •  go-up   go-down


20. Sales KJ, Grant V, Cook IH, Maldonado-Pérez D, Anderson RA, Williams AR, Jabbour HN: Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. Am J Pathol; 2010 Jan;176(1):435-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.
  • This study investigated the expression of IL-11 and role of prostaglandin F(2alpha)-F-prostanoid receptor (FP receptor) signaling in the modulation of IL-11 expression in endometrial adenocarcinoma cells.
  • IL-11 and regulator of calcineurin 1 isoform 4 (RCAN1-4) mRNA and protein expression were determined by real-time RT-PCR and/or enzyme-linked immunosorbent assay/Western blot analysis using Ishikawa endometrial adenocarcinoma cells stably expressing the FP receptor (FPS cells) and endometrial adenocarcinoma explants.
  • IL-11 mRNA expression was significantly elevated in endometrial adenocarcinoma samples compared with normal endometrium and increased with tumor grade.
  • IL-11 protein expression localized with FP receptor, IL-11Ralpha, and GP130 in the neoplastic glandular epithelium of endometrial adenocarcinomas.
  • Indeed, RCAN1-4 expression was significantly elevated in well-differentiated endometrial adenocarcinoma compared with normal endometrium and was found to decrease with tumor grade and negatively regulate IL-11 expression in vitro.
  • This study has highlighted a new mechanism regulating IL-11 expression in endometrial adenocarcinoma cells by the FP receptor via the calcium-calcineurin-nuclear factor of activated T cells pathway.
  • [MeSH-major] Calcineurin / metabolism. Calcium / metabolism. Endometrial Neoplasms / genetics. Interleukin-11 / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Muscle Proteins / metabolism. NFATC Transcription Factors / metabolism. Receptors, Prostaglandin / metabolism
  • [MeSH-minor] Aged. Cell Differentiation. Cell Proliferation. Cytokine Receptor gp130 / genetics. Cytokine Receptor gp130 / metabolism. Endometrium / metabolism. Endometrium / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Models, Biological. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Interleukin-11 / genetics. Receptors, Interleukin-11 / metabolism

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1681-90 [10861295.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1793(7):1315-24 [19348862.001]
  • [Cites] Mol Hum Reprod. 2000 Oct;6(10):907-14 [11006319.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):25-32 [11141475.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):357-64 [11162945.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):121-7 [11161848.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38787-94 [11483593.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jul;302(1):219-24 [12065720.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Oct 15;138(2):165-8 [12505265.001]
  • [Cites] Mol Hum Reprod. 2003 Feb;9(2):75-80 [12569176.001]
  • [Cites] Eur J Pharmacol. 2003 Mar 28;465(1-2):39-41 [12650831.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1825-32 [12679480.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):1-16 [2026352.001]
  • [Cites] Nucleic Acids Res. 1992 May 11;20(9):2233-9 [1317548.001]
  • [Cites] Cancer Surv. 1994;19-20:287-307 [7895220.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3115-20 [8610178.001]
  • [Cites] Biochem J. 1998 Sep 1;334 ( Pt 2):297-314 [9716487.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50537-54 [15448146.001]
  • [Cites] J Reprod Immunol. 2004 Dec;64(1-2):145-55 [15596233.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13075-80 [16131541.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4657-64 [16081631.001]
  • [Cites] Hum Reprod Update. 2005 Nov-Dec;11(6):613-30 [16006437.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):53-61 [15947972.001]
  • [Cites] J Reprod Immunol. 2006 Feb;69(1):53-64 [16310857.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):317-21 [16482637.001]
  • [Cites] J Surg Res. 2006 Apr;131(2):267-75 [16457848.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):802-8 [16614887.001]
  • [Cites] Int J Oncol. 2006 Oct;29(4):869-76 [16964382.001]
  • [Cites] Mol Cancer Res. 2006 Nov;4(11):811-20 [17114339.001]
  • [Cites] Int J Mol Med. 2007 Feb;19(2):273-8 [17203201.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):825-33 [17332920.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3023-8 [17595344.001]
  • [Cites] Endocrinology. 2007 Nov;148(11):5566-72 [17702845.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):51-61 [18316157.001]
  • [Cites] Oncogene. 2008 Apr 10;27(17):2466-77 [17968320.001]
  • [Cites] J Biol Chem. 2000 Sep 22;275(38):29907-14 [10893233.001]
  • (PMID = 20008143.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-11; 0 / Intracellular Signaling Peptides and Proteins; 0 / Muscle Proteins; 0 / NFATC Transcription Factors; 0 / RCAN1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Interleukin-11; 0 / Receptors, Prostaglandin; 0 / prostaglandin F2alpha receptor; 133483-10-0 / Cytokine Receptor gp130; EC 3.1.3.16 / Calcineurin; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2797902
  •  go-up   go-down


21. Wu W, Lin Z, Zhuang Z, Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):50-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of mammalian microRNAs in endometrioid adenocarcinoma.
  • The specific expression profiles of miRNAs have been found in many human cancers, but there are few studies on endometrioid adenocarcinoma.
  • We found the miRNA expression profile in 10 pairs of endometrioid adenocarcinoma and adjacent nontumorous endometrium using human miRNA microarray.
  • Seventeen miRNAs exhibited higher expression and six miRNAs exhibited lower expression in endometrioid adenocarcinoma samples than those in the nontumorous samples in the microarray.
  • Of those, the miR-205, miR-449, and miR-429 were greatly enriched; in contrast the miR-204, miR-99b, and miR-193b were greatly downregulated in adenocarcinoma tissues.
  • This information may provide the candidate miRNA genome for further confirming the role of miRNAs in carcinogenesis of endometrioid adenocarcinoma and potentially serving as a diagnostic or therapeutic tool in endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometrial Neoplasms / genetics. Gene Expression Profiling. MicroRNAs / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077565.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


22. Homesley HD: Present status and future direction of clinical trials in advanced endometrial carcinoma. J Gynecol Oncol; 2008 Sep;19(3):157-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Present status and future direction of clinical trials in advanced endometrial carcinoma.
  • Endometrial adenocarcinoma is staged surgically, and advanced endometrial carcinoma is considered to be FIGO stage III and IV.
  • The Gynecologic Oncology Group (GOG) has come a long way in developing new strategies in the management of advanced endometrial carcinoma.
  • Combining surgery, radiation, and chemotherapy, the 5-year survival has improved to between 40-60% in newly diagnosed advanced endometrial carcinoma.
  • Recent findings in GOG184 indicate that multiple risk factors noted at the time of surgical staging could lead to concurrent clinical trials that could be completed expeditiously rather than a subsequent ten year long phase III trial including all the various risk subgroups of patients.
  • This review is a focus on the accomplishments of the GOG in advanced endometrial carcinoma with an emphasis on future challenges.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Dec;63(3):299-303 [8946862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):1019-25 [1917597.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3902-8 [15459211.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):95-100 [15385116.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2159-66 [15169803.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):277-81 [12648575.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):349-54 [16213007.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • (PMID = 19471566.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676463
  • [Keywords] NOTNLM ; Chemotherapy / Clinical trial / Endometrial cancer / Radiotherapy / Therapy
  •  go-up   go-down


23. Pan Z, Repertinger S, Leonard R, Bewtra C, Gatalica Z, Sharma P: Cervical and endometrial metastases of appendiceal goblet cell carcinoid. Arch Pathol Lab Med; 2010 May;134(5):776-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical and endometrial metastases of appendiceal goblet cell carcinoid.
  • Appendiceal goblet cell carcinoid (GCC) is a rare tumor with histologic features of both adenocarcinoma and neuroendocrine tumor (carcinoid).
  • We report 2 cases of appendiceal GCC, one with uterine cervical involvement and the other with endometrial involvement as the initial presentations.
  • The first patient's invasive cervical signet ring cell carcinoma was diagnosed on routine screening.
  • The second patient presented with abnormal uterine bleeding, and endometrial curettage showed an adenocarcinoma with signet ring cell features.
  • Metastatic appendiceal GCC to uterine cervix and endometrium can potentially be misinterpreted as primary cervical or endometrial signet ring cell carcinoma.
  • Therefore, for any uterine cervical/endometrial signet ring cell carcinoma, a metastatic appendiceal GCC should be considered in the differential diagnosis, especially after excluding other primary sites.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Carcinoid Tumor / secondary. Endometrial Neoplasms / secondary. Uterine Cervical Neoplasms / secondary


24. Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H: Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep; 2009 Aug;22(2):233-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review).
  • Epithelial ovarian cancer (EOC) is the leading cause of death in women with gynecological malignancies.
  • Among EOC, clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC) differ from the other histological types with respect to their clinical characteristics and carcinogenesis.
  • A histologically normal ectopic endometrium bears genetic damages caused by iron-dependent oxidative stress.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Endometriosis / complications. Ovarian Neoplasms / etiology


25. Sato H, Nanjo H, Tanaka H, Tanaka T: Arias-Stella reaction in an adenomyomatous polyp of the uterus. Acta Obstet Gynecol Scand; 2007;86(1):106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arias-Stella reaction in an adenomyomatous polyp of the uterus.
  • We describe a rare case of an Arias-Stella reaction in an adenomyomatous polyp of the endometrium found in the first trimester of pregnancy.
  • An abnormal Papanicolaou's smear (highly suspicious of adenocarcinoma) prompted the resection of this pedunculated polyp.
  • Histologically, the musculature located in the center of the polyp was covered by the endometrium; numerous glands within both the endometrium and the musculature exhibited an Arias-Stella reaction.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervix Uteri / cytology. Pregnancy Complications, Neoplastic / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Pregnancy. Pregnancy Trimester, First. Vaginal Smears


26. Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M, Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol; 2008 Apr;109(1):122-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma.
  • OBJECTIVE: This study was conducted to determine whether tumor-associated macrophages (TAMs) correlate with clinicopathological features in endometrioid adenocarcinoma.
  • METHODS: 76 cases of endometrioid adenocarcinoma treated initially by hysterectomy with pelvic lymphadenectomy were retrospectively retrieved, and their histological features were evaluated.
  • TAMs may play a significant role in the biology of tumor progression of endometrial adenocarcinoma, but do not appear to be independent prognostic indicators of patient's survival.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Macrophages / pathology. Myometrium / pathology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289648.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


27. Willis SF, Barton D, Ind TE: Laparoscopic hysterectomy with or without pelvic lymphadenectomy or sampling in a high-risk series of patients with endometrial cancer. Int Semin Surg Oncol; 2006;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic hysterectomy with or without pelvic lymphadenectomy or sampling in a high-risk series of patients with endometrial cancer.
  • BACKGROUND: The purpose of the study was to determine the outcome of all patients with endometrial adenocarcinoma cancer treated by laparoscopic hysterectomy at our institution, many of whom were high-risk for surgery.
  • METHODS: Data was collected by a retrospective search of the case notes and Electronic Patient Records of the thirty eight patients who underwent laparoscopic hysterectomy for endometrial cancer at our institutions.
  • Comorbidities were present in 76% (29 patients); 40% (15 patients) had a single comorbid condition, whilst 18% (7 patients) had two, and a further 18% (7 patients) had more than two.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):932-7 [16174248.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:79-118 [14763170.001]
  • [Cites] Arch Gynecol Obstet. 2004 Jul;270(1):25-30 [12728326.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(4):305-10 [12214729.001]
  • [Cites] Curr Opin Obstet Gynecol. 2005 Feb;17(1):77-82 [15711416.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):329-35 [10985889.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):239-44 [11161866.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):378-87 [11180085.001]
  • [Cites] Gynecol Oncol. 1990 Nov;39(2):171-4 [2227591.001]
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):946-51 [16174250.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):789-93 [14984942.001]
  • [Cites] J Minim Invasive Gynecol. 2005 Mar-Apr;12(2):130-6 [15904616.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):4-9 [15790430.001]
  • [Cites] BJOG. 2005 Jan;112(1):115-7 [15663410.001]
  • (PMID = 16968556.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1586010
  •  go-up   go-down


28. Sánchez Anguiano LF, Puente Ledesma L, Lares Bayona EF, Milla Villeda RH: [Estrogenic receptors in hyperplasia and endometrial adenocarcinoma: immunohystochemical study with image analysis]. Ginecol Obstet Mex; 2007 Sep;75(9):501-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Estrogenic receptors in hyperplasia and endometrial adenocarcinoma: immunohystochemical study with image analysis].
  • [Transliterated title] Receptores de estrógenos en la hiperplasia y el adenocarcinoma de endometrio: estudio inmunohistoquímico con análisis de imagen.
  • BACKGROUND: The endometrium is a very dynamic organ that experience several half-full processes by the ovarian secretion of estradiol and progesterone.
  • The effect of hormones steroids, in the epithelial cells, endoteliales and estromales of the endometrium, is influenced by receptors of estrogens and progesterone.
  • OBJECTIVE: determine if there are any differences in the density of the estrogen receptors (ER) between the normal endometrial, the simple and complex hyperplasia, the atypical hyperplasia and the.
  • We included 143 samples that were knit together in 5 categories of the following way: Normal endometrial (n = 38), Simple hyperplasia (n = 58), Complex hyperplasia (n = 22), Atypical hyperplasia (n = 9), Adenocarcinoma (n = 16).
  • RESULTS: there were no statistical significant differences on the cell density with ER between the normal endometrial and the simple and complex hyperplasia.
  • The estrogen receptors are decreased in the atypical hyperplasia and the endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Endometrial Neoplasms / chemistry. Receptors, Estrogen / analysis
  • [MeSH-minor] Endometrial Hyperplasia. Female. Humans. Immunohistochemistry. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293624.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


29. Wilson M, Hermes R, Bainbridge J, Bassett H: A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum). J Zoo Wildl Med; 2010 Mar;41(1):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum).
  • The rhinoceros' uterus had previously been evaluated by ultrasound and diffuse endometrial hyperplasia and two benign uterine leiomyomas had been diagnosed.
  • At necropsy examination, a large, infiltrative, metastatic uterine adenocarcinoma was found multifocally throughout the uterus, scattered within the peritoneal cavity, on the diaphragm, the splenic capsule, the pleural surface of the lung and mesenteric lymph nodes.
  • [MeSH-major] Adenocarcinoma / veterinary. Lung Neoplasms / veterinary. Perissodactyla. Peritoneal Neoplasms / veterinary. Splenic Neoplasms / veterinary. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722262.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Benito V, Beltrán L, Andújar M, Lubrano A, Falcón O: Synchronous primary carcinoma of the cervix and endometrium with early lymph node recurrence. Int J Gynaecol Obstet; 2008 Nov;103(2):181-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary carcinoma of the cervix and endometrium with early lymph node recurrence.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Endometrial Neoplasms / pathology. Lymphatic Metastasis. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Female. Human papillomavirus 16 / isolation & purification. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Papillomavirus Infections / diagnosis


31. Koistinen H, Seppälä M, Knuutila S, Koistinen R: Extracellular matrix-induced changes in expression of cell cycle-related proteins and proteasome components in endometrial adenocarcinoma cells. Gynecol Oncol; 2006 Sep;102(3):546-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular matrix-induced changes in expression of cell cycle-related proteins and proteasome components in endometrial adenocarcinoma cells.
  • Whereas ECM has been shown to alter cellular morphology and reduce proliferation of HEC-1B endometrial adenocarcinoma cells, little is known about the underlying changes in gene expression.
  • METHODS: We studied by cDNA array the effects of ECM components, as present in Matrigel basement membrane cell culture matrix, on gene expression in HEC-1B endometrial adenocarcinoma cells in respect of the same cells cultured on conventional plastic surface.
  • RESULTS: As expected, several growth-promoting genes were downregulated, while many genes associated with growth restriction were upregulated in Matrigel-grown carcinoma cells.
  • The observed changes point to a less malignant phenotype of Matrigel-grown tumor cells, supported by reduced growth characteristics and morphology.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Cycle Proteins / metabolism. Endometrial Neoplasms / metabolism. Extracellular Matrix / physiology. Proteasome Endopeptidase Complex / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497364.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


32. Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE: Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res; 2008 Apr 1;68(7):2507-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer.
  • To date, no prospective studies have explored the relationship between the use of aspirin, other nonsteroidal anti-inflammatory medications (NSAID), and acetaminophen and endometrial adenocarcinoma.
  • Of the 82,971 women enrolled in a prospective cohort study, 747 developed medical record-confirmed invasive endometrial cancer over a 24-year period.
  • Cox regression models calculated multivariate relative risks (MV RR), controlling for body mass index (BMI), postmenopausal hormone (PMH) use, and other endometrial cancer risk factors.
  • Currency, duration, and quantity of aspirin were not associated with endometrial cancer risk overall [current use: MV RR, 1.03; 95% confidence interval (CI) 0.83-1.27; >10 years of use: MV RR, 1.01; 95% CI, 0.78-1.30; and cumulative average >7 tablets per week: (MV RR, 1.10; 95% CI, 0.84-1.44)].
  • However, stratified analyses showed that a lower risk of endometrial cancer among obese (BMI, >or=30 kg/m(2)) women was seen with current aspirin use (MV RR, 0.66; 95% CI, 0.46-0.95).
  • The use of other NSAIDs or acetaminophen was not associated with endometrial cancer.
  • Our data suggest that use of aspirin or other NSAIDs does not play an important role in endometrial cancer risk overall.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 2000 Jan;182(1 Pt 1):23-9 [10649152.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):447-54 [17316360.001]
  • [Cites] Epidemiology. 2001 Jan;12(1):88-93 [11138826.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Obstet Gynecol. 2001 Mar;97(3):423-7 [11239649.001]
  • [Cites] J Exp Med. 2001 Mar 19;193(6):F23-6 [11257144.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26208-16 [12006564.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):801-7 [12209724.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):81-93 [12385835.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531-43 [12496040.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1586-91 [12496048.001]
  • [Cites] Ann Med. 2002;34(6):428-33 [12523498.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6096-101 [14522941.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):501-7 [14623550.001]
  • [Cites] J Natl Cancer Inst. 2004 Jan 7;96(1):22-8 [14709735.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 7;96(7):524-8 [15069114.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):525-9 [15226764.001]
  • [Cites] Am J Epidemiol. 1982 Aug;116(2):333-42 [7114042.001]
  • [Cites] Biol Rev Camb Philos Soc. 1986 Nov;61(4):313-28 [3542071.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):319-25 [3605058.001]
  • [Cites] Contraception. 1987 Jul;36(1):23-35 [3311624.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4399-404 [3390835.001]
  • [Cites] Int J Cancer. 1989 May 15;43(5):795-9 [2714884.001]
  • [Cites] Epidemiology. 1990 Nov;1(6):466-73 [2090285.001]
  • [Cites] Int J Cancer. 1991 Aug 19;49(1):38-43 [1874568.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):567-71 [1537622.001]
  • [Cites] J Natl Cancer Inst. 1993 Aug 4;85(15):1220-4 [8331682.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1174-6 [12748469.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:1-24 [12795046.001]
  • [Cites] Endocrinology. 1996 Dec;137(12):5739-42 [8940410.001]
  • [Cites] J Womens Health. 1997 Feb;6(1):49-62 [9065374.001]
  • [Cites] Fertil Steril. 1998 Aug;70(2):371-3 [9696240.001]
  • [Cites] Lancet. 1999 May 29;353(9167):1824-8 [10359406.001]
  • [Cites] Int J Cancer. 1999 Jul 2;82(1):38-42 [10360818.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1131-7 [10393721.001]
  • [Cites] Contraception. 2004 Dec;70(6):451-62 [15541406.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):901-7 [15546508.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):85-7 [15626590.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):996-1001 [15645490.001]
  • [Cites] Am J Obstet Gynecol. 2005 Apr;192(4):1262-71; discussion 1271-3 [15846217.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):47-55 [15998890.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2840-7 [16364998.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2923-8 [16365011.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):365-75 [17339622.001]
  • [Cites] J Clin Epidemiol. 2000 Apr;53(4):385-91 [10785569.001]
  • (PMID = 18381460.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / CA117979-04; United States / NCI NIH HHS / CA / K07 CA117979-04; United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / K07 CA117979-01; United States / NCI NIH HHS / CA / CA117979-02; United States / NCI NIH HHS / CA / CA117979-01; United States / NCI NIH HHS / CA / K07 CA117979; United States / NCI NIH HHS / CA / K07 CA117979-02; United States / NCI NIH HHS / CA / K07 CA117979-03; United States / NCI NIH HHS / CA / CA117979-03; United States / NCI NIH HHS / CA / 5K07 CA117979-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 362O9ITL9D / Acetaminophen; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ NIHMS191688; NLM/ PMC2857531
  •  go-up   go-down


33. Wang C, Norton JT, Ghosh S, Kim J, Fushimi K, Wu JY, Stack MS, Huang S: Polypyrimidine tract-binding protein (PTB) differentially affects malignancy in a cell line-dependent manner. J Biol Chem; 2008 Jul 18;283(29):20277-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RNA processing is altered during malignant transformation, and expression of the polypyrimidine tract-binding protein (PTB) is often increased in cancer cells.
  • Although some data support that PTB promotes cancer, the functional contribution of PTB to the malignant phenotype remains to be clarified.
  • Here we report that although PTB levels are generally increased in cancer cell lines from multiple origins and in endometrial adenocarcinoma tumors, there appears to be no correlation between PTB levels and disease severity or metastatic capacity.
  • Reduction of PTB inhibits the invasive behavior of two cancer cell lines in Matrigel invasion assays but enhances the invasive behavior of another.
  • These data demonstrate that PTB is not oncogenic and can either promote or antagonize a malignant trait dependent upon the specific intra-cellular environment.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):800-6 [16282332.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 May;6(5):386-98 [15956978.001]
  • [Cites] Bioessays. 2006 Apr;28(4):378-86 [16547952.001]
  • [Cites] Nat Struct Mol Biol. 2006 Sep;13(9):839-48 [16936729.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):8755-69 [16982681.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4961-8 [17310993.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1221-4 [10728679.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):23869-76 [10791952.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):938-43 [11158574.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3281-8 [11313454.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):8535-43 [11116151.001]
  • [Cites] RNA. 2001 Jun;7(6):819-32 [11421360.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(23):8238-46 [11710333.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):3808-20 [11739782.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):943-9 [12419237.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2524-33 [12467066.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 15;31(2):639-46 [12527772.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):419-37 [12600935.001]
  • [Cites] RNA. 2003 Apr;9(4):443-56 [12649496.001]
  • [Cites] Mol Biol Cell. 2003 Jun;14(6):2425-35 [12808040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8776-81 [12851456.001]
  • [Cites] Annu Rev Biochem. 2003;72:291-336 [12626338.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6154-7 [14559795.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):9-14 [14769134.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4174-83 [15121839.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4652-60 [15269137.001]
  • [Cites] Cancer Res. 1984 Aug;44(8):3522-9 [6744277.001]
  • [Cites] Biochemistry. 1990 May 22;29(20):4966-70 [2114170.001]
  • [Cites] Cell. 1991 Apr 5;65(1):13-24 [1707342.001]
  • [Cites] Genes Dev. 1991 Jul;5(7):1224-36 [1906035.001]
  • [Cites] Genes Dev. 1991 Jul;5(7):1237-51 [1906036.001]
  • [Cites] Nucleic Acids Res. 1992 Jul 25;20(14):3671-8 [1641332.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2993-3001 [8474457.001]
  • [Cites] J Virol. 1994 Feb;68(2):941-50 [8289396.001]
  • [Cites] Cell. 1994 Sep 9;78(5):739-50 [8087842.001]
  • [Cites] Virology. 1995 Dec 20;214(2):660-3 [8553572.001]
  • [Cites] RNA. 1995 Nov;1(9):924-38 [8548657.001]
  • [Cites] Genes Dev. 1996 Jan 15;10(2):208-19 [8566754.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5400-8 [8816452.001]
  • [Cites] J Cell Biol. 1997 Jun 2;137(5):965-74 [9166399.001]
  • [Cites] RNA. 1997 Jul;3(7):764-78 [9214659.001]
  • [Cites] Biochemistry. 1997 Sep 30;36(39):11881-90 [9305981.001]
  • [Cites] Curr Biol. 1997 Nov 1;7(11):R705-8 [9382788.001]
  • [Cites] Biochem J. 1998 Apr 1;331 ( Pt 1):169-75 [9512476.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1627-36 [9816342.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):78-85 [9858533.001]
  • [Cites] Electrophoresis. 1999 Apr-May;20(4-5):1082-6 [10344288.001]
  • [Cites] Gene. 2005 Jan 3;344:1-20 [15656968.001]
  • [Cites] J Cell Biochem. 2005 May 15;95(2):217-25 [15770648.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):676-81 [15841311.001]
  • [Cites] Nat Methods. 2004 Dec;1(3):233-9 [15782199.001]
  • [Cites] Trends Biochem Sci. 2006 Feb;31(2):73-6 [16403634.001]
  • (PMID = 18499661.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM 078555-01; United States / NIGMS NIH HHS / GM / GM 070967; United States / NCI NIH HHS / CA / R21 CA127674-01A2; United States / NCI NIH HHS / CA / CA127674-01A2; United States / NCI NIH HHS / CA / R21 CA127674; United States / NCI NIH HHS / CA / CA 097761
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Small Interfering; 139076-35-0 / Polypyrimidine Tract-Binding Protein; EC 3.4.22.- / Caspase 2
  • [Other-IDs] NLM/ PMC2459264
  •  go-up   go-down


34. Roncati L, Barbolini G, Ghirardini G, Rivasi F: Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report. Int J Surg Pathol; 2010 Dec;18(6):561-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report.
  • This mass was noted on CT scan and considered metastatic in nature since following a bioptical diagnosis of endometrial adenocarcinoma.
  • Hysterectomy and bilateral salpingectomy and ovariectomy were performed and a second minor mature solid teratoma was discovered inside the right ovary.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Teratoma / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282291.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Zhang Y, Zhang Y, Lin QH: [Progesterone-modulated proteins in human endometrial cancer cell line Ishikawa]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug;26(8):1110-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progesterone-modulated proteins in human endometrial cancer cell line Ishikawa].
  • OBJECTIVE: To identify proteins associated with growth inhibitory effects of progesterone in Ishikawa endometrial adenocarcinoma cell line (Ishikawa).
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Line, Tumor. Down-Regulation / drug effects. Electrophoresis, Gel, Two-Dimensional. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Mass Spectrometry. Megestrol Acetate / pharmacology. Up-Regulation / drug effects

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939895.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteins; 0 / Proteome; 4G7DS2Q64Y / Progesterone; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


36. Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, Navarra P: Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol; 2007 Jan 29;264(1-2):44-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.
  • It has been previously shown that corticotropin-releasing hormone (CRH) exerts antiproliferative activity on an estrogen-dependent tumor cell line, i.e. human endometrial adenocarcinoma Ishikawa (IK) cells.
  • Here we have investigated the effects of CRH on another estrogen-dependent tumor cell line, human breast cancer MCF7 cells.
  • We have also investigated the putative source of CRH acting on breast cancer cells; we found that MCF7 cells express CRH mRNA under basal conditions and secrete sizable amounts of immunoreactive CRH, which leads to postulate the existence of paracrine-autocrine inhibitory mechanism operated by CRH in breast cancer cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hormones.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097220.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CRF receptor type 1; 0 / Hormones; 0 / Pyrimidines; 0 / Pyrroles; 0 / Receptors, Corticotropin-Releasing Hormone; 0 / antalarmin; 4TI98Z838E / Estradiol; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


37. Trimble EL, Harlan LC, Clegg LX, Stevens JL: Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States. Gynecol Oncol; 2005 Mar;96(3):741-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States.
  • INTRODUCTION: Non-Hispanic black women are less often diagnosed with endometrial cancer than are non-Hispanic white women, but are more likely to die of their disease.
  • METHODS: The Surveillance, Epidemiology, and End-Results Program data were used to sample women newly diagnosed in 1998 with cancer of the corpus uteri.
  • A total of 711 women with no previous diagnosis of cancer were selected.
  • CONCLUSIONS: Our study did not show any difference in recommended therapy for women with uterine adenocarcinoma among NH black women, NH white women, and Hispanic women.
  • We must look for other factors, therefore, to explain the disparities in cancer outcome observed among NH black women with endometrial cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721420.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Mylonas I, Makovitzky J, Shabani N, Richter DU, Kuhn C, Jeschke U, Briese V, Friese K: Leukaemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue. Eur J Obstet Gynecol Reprod Biol; 2005 Jan 10;118(1):101-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue.
  • Therefore, the aim of this study was to determine the frequency and tissue distribution of LIF in normal, hyperplastic and malignant endometrium.
  • STUDY DESIGN: Paraffin-fixed endometrial tissue was obtained from normal premenopausal women (n = 15), endometrial hyperplasia (n = 20), endometroid adenocarcinoma (n = 32) and endometrial polyps (n = 9).
  • RESULTS: The lowest expression of LIF was observed in endometrial adenocarcinomas compared to all groups, while endometrial polyps expressed the highest LIF immunostaining.
  • The highest expression of LIF was observed in endometrial polyps.
  • Simple hyperplasia showed a significantly higher LIF expression than proliferative endometrium and adenocarcinoma.
  • Adenomatous hyperplasia (AH) grade I-III had a significantly higher LIF expression than adenocarcinoma.
  • The lowest expression of LIF was observed in adenocarcinoma, being statistically significant compared to all groups.
  • CONCLUSION: LIF was immunohistochemically demonstrated in normal, hyperplastic and malignant endometrial tissue, suggesting a widespread but complex role for LIF in hyperplastic and malignant endometrial growth regulation.
  • AH I-III also expressed LIF with statistically higher immunostaining than adenocarcinoma.
  • Since AH III can be considered as a precursor of endometrial cancer, LIF could be a marker of cell transformation.
  • [MeSH-major] Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Immunohistochemistry. Interleukin-6 / analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Female. Humans. Leukemia Inhibitory Factor. Polyps / chemistry. Premenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15596282.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor
  •  go-up   go-down


39. Ditto A, Martinelli F, Carcangiu ML, Hanozet F, Solima E, Barisella M, Cerrotta A, Raspagliesi F: Incidental diagnosis of primary vaginal adenocarcinoma of intestinal type: a case report and review of the literature. Int J Gynecol Pathol; 2007 Oct;26(4):490-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental diagnosis of primary vaginal adenocarcinoma of intestinal type: a case report and review of the literature.
  • Primary vaginal adenocarcinoma of intestinal type is a rare malignant gynecologic disease.
  • A 53-year-old woman was admitted to our institution with a diagnosis of endometrial adenocarcinoma.
  • The patient underwent surgery for endometrial cancer and wedge resection of the vaginal lesion.
  • The diagnosis of primary vaginal adenocarcinoma of intestinal type was obtained after standard and immunohistochemical analyses of the specimen.
  • No endometrial cancer was detected in the specimen.
  • Extensive radiological investigations and careful immunohistochemical analysis of the specimen are needed for a correct diagnosis of vaginal adenocarcinoma of intestinal type.
  • [MeSH-major] Adenocarcinoma / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Endometrial Neoplasms / pathology. Female. Gynecologic Surgical Procedures. Humans. Immunohistochemistry. Incidental Findings. Intestinal Neoplasms / pathology. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Radiotherapy

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885503.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Gil da Costa RM, Santos M, Amorim I, Lopes C, Pereira PD, Faustino AM: An immunohistochemical study of feline endometrial adenocarcinoma. J Comp Pathol; 2009 May;140(4):254-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical study of feline endometrial adenocarcinoma.
  • Feline endometrial adenocarcinomas are uncommon malignant neoplasms that have to date been poorly characterized.
  • The present immunohistochemical study describes the expression of the pancytokeratins AE1 and AE3, cytokeratin-14, vimentin, alpha-actin, cyclo-oxygenase-2, E-cadherin, beta-catenin, the progesterone receptor, the oestrogen receptor and caveolin-1 within normal feline uterine tissue and tissue from six cats with endometrial adenocarcinoma.
  • Synthesis of cyclo-oxygenase-2 and reduced expression of progesterone receptors may be involved in the neoplastic transformation of feline endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / veterinary. Cat Diseases / metabolism. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / veterinary. Immunohistochemistry / veterinary

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201419.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Yalta T, Atay L, Atalay F, Caydere M, Gonultas M, Ustun H: E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas. J Int Med Res; 2009 Jan-Feb;37(1):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas.
  • This study examined the frequency of E-cadherin expression in endometrial biopsy or hysterectomy specimens from patients diagnosed with endometrial adenocarcinoma and in normal endometrial tissue specimens.
  • Twenty-three endometrioid carcinomas and nine non-endometrioid (four papillary serous and five clear cell) carcinomas were studied, along with 10 normal endometrial tissue specimens as controls.
  • E-cadherin expression was significantly less frequent in non-endometrioid carcinomas compared with endometrioid carcinomas and controls.
  • There was no statistically significant difference in the frequency of E-cadherin expression between endometrioid carcinomas and controls.
  • In conclusion, this study demonstrated that uterine non-endometrioid (papillary serous and clear cell) carcinomas were less likely to express E-cadherin compared with endometrioid carcinomas and normal endometrial tissue.
  • This may help to explain the more aggressive behaviour of non-endometrioid carcinomas.
  • [MeSH-major] Cadherins / metabolism. Endometrial Neoplasms / classification. Endometrial Neoplasms / metabolism. Endometrium / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215686.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


42. Kurman RJ, McConnell TG: Precursors of endometrial and ovarian carcinoma. Virchows Arch; 2010 Jan;456(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursors of endometrial and ovarian carcinoma.
  • This review discusses precursor lesions of endometrial and ovarian carcinoma with an emphasis on the unique molecular alterations that have led to the development of binary classification schemes for tumors of both the endometrium and ovary.
  • While such a system is well established for endometrial carcinoma, only recently has a binary classification scheme been proposed for ovarian carcinoma.
  • For both, the morphologic and molecular genetic-defining characteristics of their respective precursor lesions are described in detail.
  • Furthermore, similarities and differences of the precursor lesions of specific tumors of these two genital tract organs are also addressed with a brief discussion of the clinical implications of their diagnosis.
  • [MeSH-major] Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / pathology. Female. Humans. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):81-6 [7557621.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5308-14 [1913654.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):209-17 [11161379.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):55-9 [10076565.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3254-8 [9699651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5 [8506342.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2263-9 [18369088.001]
  • [Cites] Gynecol Oncol. 1992 Jul;46(1):51-4 [1634141.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):314-21 [11109159.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):779-85 [16721043.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1818-27 [12932658.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] Cancer Res. 1998 May 15;58(10 ):2095-7 [9605750.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):207-23 [15306933.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):238-44 [8631545.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92 (11):924-30 [10841828.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):55-65 [10739691.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Histopathology. 1995 Oct;27(4):367-71 [8847068.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1318-27 [8413413.001]
  • [Cites] Am J Pathol. 1991 Oct;139(4):777-85 [1656759.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23 ):13513-8 [9811831.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):614-24 [16699316.001]
  • [Cites] Hum Pathol. 2000 May;31(5):539-57 [10836293.001]
  • [Cites] Arch Pathol Lab Med. 1981 Nov;105(11):615-8 [6895302.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):103-14 [17413975.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):883-7 [16806438.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):182-8 [7856726.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):378-81 [12893203.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):600-10 [1599038.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1216-21 [8040889.001]
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):844-53 [19342944.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):318-25 [18580308.001]
  • [Cites] Anal Quant Cytol Histol. 1986 Mar;8(1):46-8 [3954843.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(4):389-92 [17009632.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1895-8 [11395362.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):37-41 [12496696.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1088-91 [10880552.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6915-8 [15466181.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1088-95 [9506354.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Am J Obstet Gynecol. 1993 Jul;169(1):181-2 [8392791.001]
  • [Cites] J Pathol. 2006 Apr;208(5):708-13 [16429393.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91 [17692090.001]
  • [Cites] Histopathology. 1997 Mar;30(3):249-55 [9088954.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1750-2 [10749149.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1513-9 [8360934.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] Pathology. 1979 Jan;11(1):5-26 [431978.001]
  • [Cites] Gynecol Oncol. 1999 Sep;74(3):385-94 [10479498.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):1012-9 [9706982.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):814-24 [10679651.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):707-23 [15897738.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1597-601 [19349352.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Histopathology. 1981 Jan;5(1):61-8 [7216177.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1102-8 [10478671.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1163-6 [8134118.001]
  • [Cites] Jpn J Cancer Res. 1998 Oct;89(10 ):985-90 [9849574.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:44-50 [11093061.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):298-305 [1473741.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1604-7 [8137266.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12 ):2500-3 [9635567.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2073-81 [18720479.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • (PMID = 19859732.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 88
  •  go-up   go-down


43. Gien LT, Barbera L, Kupets R, Saskin R, Paszat L: Utilization of preoperative imaging in uterine cancer patients. Gynecol Oncol; 2009 Nov;115(2):226-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilization of preoperative imaging in uterine cancer patients.
  • This study evaluates patterns of preoperative ultrasound, CT and MRI use among uterine cancer patients in Ontario.
  • METHODS: This population-based study identified women diagnosed with uterine malignancy from 1995-2005 in the Ontario Cancer Registry.
  • Record linkages were made to other healthcare databases to characterize residence, socioeconomic status, comorbidities, and timing of investigations surrounding diagnosis.
  • RESULTS: We identified 12,522 women who received surgery for uterine adenocarcinoma or sarcoma, of which 9145 (73%) had a preoperative ultrasound, and 1148 (9.2%) had a preoperative CT and/or MRI.
  • Higher rates of CT/MRI use were associated with non-endometrioid high-risk histology (33.5% vs 14.6%, p<0.0001).
  • Time from diagnosis to surgery was 2 weeks longer if a preoperative CT/MRI was done.
  • CONCLUSIONS: The rate of preoperative CT and MRI use in patients with uterine cancer has increased twice as much as the reported rate in cancer patients overall.
  • Given the questionable utility of preoperative CT/MRI in this disease, guidelines should be developed for use of these imaging tests in uterine cancer, especially when use is associated with a delay in surgery.
  • [MeSH-major] Adenocarcinoma / diagnosis. Sarcoma / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19683807.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, Colás E, Llauradó M, Alazzouzi H, Planagumá J, Lohmann MA, Garcia J, Castellvi S, Ramon y Cajal J, Gil-Moreno A, Xercavins J, Alameda F, Reventós J: Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol; 2008 Feb;108(3-5):221-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel molecular profiles of endometrial cancer-new light through old windows.
  • Endometrial carcinoma (EC) is the most common gynecological malignancy in the western world.
  • A widely accepted dualistic model, which has been established on a morphological basis, differentiates EC into two broad categories: Type I oestrogen-dependent adenocarcinoma with an endometrioid morphology and Type II non-oestrogen-dependent EC with a serous papillary or clear cell morphology.
  • Molecular genetic evidence indicates that endometrial carcinoma, as described in other malignancies, likely develops as the result of a stepwise accumulation of alterations in cellular regulatory pathways, such as oncogene activation and tumor suppressor gene inactivation, which lead to dysfunctional cell growth.
  • In type I endometrioid endometrial cancer, PTEN gene silencing in conjunction with defects in DNA mismatch repair genes, as evidenced by the microsatellite instability phenotype, or mutations in the K-ras and/or beta-catenin genes, are recognized major alterations, which define the progression of the normal endometrium to hyperplasia, to endometrial intraepithelial neoplasia, and then on to carcinoma.
  • In contrast, Type II cancers show mutations of TP53 and Her-2/neu and seem to arise from a background of atrophic endometrium.
  • RUNX1, a transcription factor, was recently identified as one of the most highly over-expressed genes in a microarray study of invasive endometrial carcinoma.
  • These studies, as well as those conducted for other genes possibly involved in the mitotic checkpoint as a major mechanism of carcinogenesis in non-endometrioid endometrial cancer, could help in understanding the differences in the biology and the clinical outcome among histological types.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / pathology. Core Binding Factor Alpha 2 Subunit / genetics. Cystadenocarcinoma, Papillary / pathology. DNA Mismatch Repair. Female. Genes, erbB-2 / genetics. Genes, p53 / genetics. Genes, ras / genetics. Humans. Microsatellite Instability. Neoplasms, Hormone-Dependent / pathology. Oncogenes / genetics. PTEN Phosphohydrolase / genetics. Receptors, Estrogen / genetics. Receptors, Progesterone / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061438.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 86
  •  go-up   go-down


45. Skórzewska K, Radowicki S, Matuszkiewicz-Rowinska J, Szlendak-Sauer K: Morphological changes in endometrium of hemodialyzed women of reproductive age. Gynecol Endocrinol; 2007 Sep;23(9):523-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological changes in endometrium of hemodialyzed women of reproductive age.
  • AIM: The aim of the study was to evaluate endometrial morphology and its correlation with hormonal profile in uremic women of reproductive age undergoing hemodialysis.
  • MATERIALS AND METHODS: Sixty-three hemodialyzed women aged 18-45 years were enrolled into the study, 38 of whom gave their informed consent to undergo endometrial aspiration biopsy and measurement of hormonal profile.
  • RESULTS: Abnormal endometrial morphology was noted in 79% of the hemodialyzed women.
  • Atrophic endometrium was observed in almost all uremic patients with secondary amenorrhea.
  • Endometrial biopsy revealed one case of adenocarcinoma in situ.
  • Analysis of the relationship between hormonal profile and endometrial morphology revealed the substantial influence of estradiol on endometrium.
  • CONCLUSIONS: Abnormal endometrial changes are often noted in uremic women of reproductive age undergoing hemodialysis.
  • Endometrial biopsy should be carried out as a safe and convenient procedure for the detection of pathological changes in uremic women.
  • [MeSH-major] Endometrium / pathology. Renal Dialysis. Uremia / complications. Uremia / therapy. Uterine Diseases / etiology

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943547.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


46. Buchynska LG, Nesina IP, Kashuba EV: Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia. Exp Oncol; 2007 Dec;29(4):287-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia.
  • AIM: To study the expression of p53, MDM2, and p14 ARF in the highly, moderately and low differentiated endometrial adenocarcinomas, compared to hyperplasia.
  • MATERIAL AND METHODS: Surgical material and the scrapes of endometrial cancer, glandular and atypical hyperplasia patients.
  • RESULTS: High p53 expression level is accompanied by decreased level of MDM2 expression in endometrial cancers.
  • On contrary, in endometrial hyperplasia, there was clear connection between the expression levels of p53 and MDM2.
  • We hypothesize that the high p53 and low MDM2 levels in endometrial cancers could arise due to the inhibition of transcriptional activity of p53 by its binding to estrogen receptors.
  • CONCLUSION: High p53 expression level with low MDM2 and p14 ARF levels may be the characteristic features of low differentiated endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Proto-Oncogene Proteins c-mdm2 / biosynthesis. Tumor Suppressor Protein p14ARF / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199985.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


47. Guèye SM, Aissi G, Youssef C, Raiga J, Arnouuld N, Bellocq JP, Moreau JC, Brettes JP: [Advantages of laparoscopic assisted vaginal hysterectomy in surgery of endometrial carcinoma]. Dakar Med; 2007;52(1):62-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advantages of laparoscopic assisted vaginal hysterectomy in surgery of endometrial carcinoma].
  • [Transliterated title] Avantages de la voie vaginale coelio-assistée dans la chirurgie des cancers de l'endomètre.
  • INTRODUCTION: In to respect the principles of oncological surgery and to reduce the operative morbidity, the authors of this study propose to find the proper place of the laparoscopic-assisted vaginal hysterectomy in the surgery of endometrial carcinomas.
  • CONCLUSION: Considering these results, the authors retain that, in primary stages (I-II, FIGO), laparoscopic-assisted vaginal hysterectomy represents a real option in the surgery of endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Hysterectomy, Vaginal / methods. Laparoscopy. Laparotomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Endometrium / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102096.001).
  • [ISSN] 0049-1101
  • [Journal-full-title] Dakar médical
  • [ISO-abbreviation] Dakar Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Senegal
  •  go-up   go-down


48. Siami K, McCluggage WG, Ordonez NG, Euscher ED, Malpica A, Sneige N, Silva EG, Deavers MT: Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol; 2007 Nov;31(11):1759-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas.
  • Thyroid transcription factor-1 (TTF-1) is widely used in the diagnosis of lung and thyroid carcinomas.
  • Although there have been reports of TTF-1 immunoreactivity in tumors other than those originating in the lung or thyroid, endocervical and endometrial adenocarcinomas have not been studied in large numbers.
  • Twenty-eight endocervical (9 well, 12 moderately, and 7 poorly differentiated), 32 endometrioid endometrial adenocarcinomas (11 grade I, 8 grade II, and 13 grade III), and 13 uterine serous carcinomas were retrieved and stained with TTF-1.
  • TTF-1 expression was seen in 1 of 28 (4%) of the endocervical adenocarcinomas and this was 4+ in distribution.
  • The positive endocervical carcinoma was poorly differentiated.
  • TTF-1 expression was present in 6 of 32 (19%) of the endometrioid adenocarcinomas (1 grade I, 2 grade II, and 3 grade III) and varied from 1+ to 4+ in distribution.
  • Only 2 of 32 (6%) of the endometrioid adenocarcinomas stained diffusely (4+).
  • There was no apparent correlation between the degree of differentiation and TTF-1 positivity in the adenocarcinomas.
  • Three of 13 (23%) serous carcinomas were also positive (1 case 5+ and 2 cases 1+).
  • Although TTF-1 is generally considered to be a relatively specific marker for lung and thyroid neoplasms, the occasional expression of endometrial and endocervical carcinomas should be kept in mind when evaluating neoplasms of uncertain origin.
  • It should also be taken into consideration in the evaluation of adenocarcinomas involving the lung in patients with a history of a gynecologic malignancy.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cystadenocarcinoma, Serous / chemistry. Endometrial Neoplasms / chemistry. Nuclear Proteins / analysis. Transcription Factors / analysis. Uterine Cervical Neoplasms / chemistry. Uterine Neoplasms / chemistry


49. Hebbar V, Damera G, Sachdev GP: Differential expression of MUC genes in endometrial and cervical tissues and tumors. BMC Cancer; 2005 Sep 27;5:124
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of MUC genes in endometrial and cervical tissues and tumors.
  • The objective of this study was to investigate the expression of human MUC genes (MUC1, MUC2, MUC5B, MUC5AC and MUC8) in human endometrium and cervix, and to compare and quantitate the expression of MUC genes in normal and cancerous tissues.
  • RESULTS: Of the five-mucin genes studied, MUC1, MUC5B and MUC8 showed high expression levels in the normal and cancerous endometrial and cervical tissues, MUC2 and MUC5AC showed considerably lower expression.
  • Statistically, higher levels of MUC1, MUC5B and MUC8 were observed in endometrial adenocarcinomas compared to normal tissues.
  • CONCLUSION: Endometrial tumors showed increased expression of MUC1, MUC5B and MUC8 over normal tissues.
  • Low to neglible levels of MUC2 and MUC5AC were observed in all studied endometrial and cervical tissues.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1996 Mar-Apr;53(2):118-26 [8604237.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):856-61 [11093805.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Biochim Biophys Acta. 1998 Apr 28;1406(3):251-9 [9630659.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15386-96 [11278696.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] J Korean Med Sci. 2002 Feb;17(1):29-33 [11850585.001]
  • [Cites] J Pathol. 2002 Aug;197(5):632-7 [12210083.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Jpn J Clin Oncol. 2002 Dec;32(12):525-9 [12578901.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Mar;28(3):267-70 [12594051.001]
  • [Cites] Am J Reprod Immunol. 1996 Mar;35(3):261-6 [8962658.001]
  • [Cites] Fertil Steril. 1996 Aug;66(2):316-26 [8690123.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Mar;16(3):232-41 [9070607.001]
  • [Cites] Biol Reprod. 1997 Apr;56(4):999-1011 [9096884.001]
  • [Cites] J Surg Oncol. 2003 Aug;83(4):253-60 [12884239.001]
  • [Cites] Hum Reprod. 1988 Oct;3(7):826-34 [3182973.001]
  • [Cites] J Biol Chem. 1989 Apr 15;264(11):6480-7 [2703501.001]
  • [Cites] Hum Reprod. 1989 Apr;4(3):236-42 [2469695.001]
  • [Cites] Biochem J. 1990 Mar 15;266(3):757-63 [1691631.001]
  • [Cites] Eur J Biochem. 1990 May 20;189(3):475-86 [2112460.001]
  • [Cites] Tumour Biol. 1990;11(5):274-86 [1697426.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] J Reprod Fertil. 1991 Jul;92(2):525-41 [1886107.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1992;27(1-2):57-92 [1727693.001]
  • [Cites] Am J Physiol. 1992 Oct;263(4 Pt 1):L413-29 [1415719.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Dec;7(6):557-64 [1449803.001]
  • [Cites] Fertil Steril. 1993 Dec;60(6):1011-9 [7694876.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] Eur J Biochem. 1994 Sep 1;224(2):787-95 [7925397.001]
  • [Cites] Crit Rev Oncol Hematol. 1994 Dec;17(3):153-80 [7865137.001]
  • [Cites] Hum Reprod. 1995 Jan;10(1):98-102 [7745080.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2681-90 [7780985.001]
  • [Cites] Endocrinology. 1995 Aug;136(8):3639-47 [7628404.001]
  • [Cites] Biol Reprod. 1999 Jan;60(1):58-64 [9858486.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Ann Thorac Surg. 1999 Mar;67(3):810-4 [10215233.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):45-54 [10227724.001]
  • [Cites] Cancer Lett. 1999 Jul 19;142(1):121-7 [10424790.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] Int J Cancer. 1999 Oct 22;84(5):466-9 [10502721.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2240-5 [10521973.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):398-403 [15816444.001]
  • [Cites] J Histochem Cytochem. 2000 Mar;48(3):377-88 [10681391.001]
  • [Cites] Biosci Rep. 1999 Oct;19(5):473-83 [10763814.001]
  • [Cites] Clin Biochem. 2000 Apr;33(3):167-73 [10913513.001]
  • [Cites] Tumour Biol. 1996;17(3):176-92 [8638091.001]
  • (PMID = 16188033.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL34012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC5B protein, human; 0 / MUC8 protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-5B; 0 / Mucins; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC1249559
  •  go-up   go-down


50. Pollock J: Letter to the editor in response to "Stage 1, grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence". Gynecol Oncol; 2010 Jun;117(3):507; author reply 507-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Letter to the editor in response to "Stage 1, grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence".
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gynecol Oncol. 2010 Jan;116(1):10-4 [19875158.001]
  • (PMID = 20189231.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


51. Juretzka MM, O'Hanlan KA, Katz SL, El-Danasouri I, Westphal LM: Embryo cryopreservation after diagnosis of stage IIB endometrial cancer and subsequent pregnancy in a gestational carrier. Fertil Steril; 2005 Apr;83(4):1041
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryo cryopreservation after diagnosis of stage IIB endometrial cancer and subsequent pregnancy in a gestational carrier.
  • OBJECTIVE: To describe a case of embryo cryopreservation before hysterectomy and bilateral salpingo-oophorectomy for endometrial cancer.
  • PATIENT(S): An infertile woman with endometrial biopsy demonstrating grade II/III moderately differentiated endometrial adenocarcinoma.
  • INTERVENTION(S): A Progestasert intrauterine device (IUD) was inserted into the uterine cavity to potentially reduce tumor proliferation during the stimulation cycle followed by oocyte retrieval and cryopreservation of 14 embryos.
  • CONCLUSION(S): Embryo cryopreservation and use of a gestational carrier may offer a fertility option for patients with endometrial malignancies without substantially delaying treatment.
  • [MeSH-major] Adenocarcinoma / surgery. Cryopreservation / methods. Embryo Transfer. Embryo, Mammalian / physiology. Endometrial Neoplasms / surgery. Infertility, Female / therapy. Pregnancy Outcome. Surrogate Mothers


52. Oshiro H, Miyagi Y, Kawaguchi Y, Rino Y, Arai H, Asai-Sato M, Nakayama H, Yamanaka S, Inayama Y, Fukushima N: Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm. Pathol Int; 2008 Jul;58(7):456-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm.
  • Reported herein is a case of endometrial adenocarcinoma without myometrial invasion that metastasized to the pancreas in a 69-year-old Japanese woman who had a history of hysterectomy.
  • Excised in distal pancreatectomy, the tumor was diagnosed as a pancreatic primary, an invasive papillary adenocarcinoma at first, but both the endometrial tumor and the pancreatic tumor demonstrated similar morphology and immunohistochemistry.
  • Furthermore, the identical nucleotide mutation of TP53 gene was observed from both the endometrial and pancreatic tumors.
  • The pancreatic tumor was therefore confirmed to be a metastasis from the primary endometrial adenocarcinoma.
  • Metastasis to the pancreas from endometrial carcinoma is extremely rare but must be considered even if the previous cancer was treated at an early stage.
  • Histopathological comparison study and genetic analysis are important for the correct diagnosis of metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Aged. Base Sequence. Diagnosis, Differential. Female. Genes, p53. Humans. Hysterectomy. Immunohistochemistry. Molecular Sequence Data. Mutation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577117.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


53. Minár L, Petrovová D, Kümmel J: [Cancer of endometrium--rare variant of remote metastases]. Ceska Gynekol; 2009 Oct;74(5):383-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of endometrium--rare variant of remote metastases].
  • OBJECTIVE: Information sheet about cancer of endometrium as the most frequently gynecological malignant tumor.
  • METHODS: Literature review about cancer of endometrium with illustrative case reports.
  • CONCLUSIONS: Cancer of endometrium is the most frequently malignant tumor of female reproductive organs in developed countries.
  • Distant metastasis is less common, most frequently seen with a lung, but in the cencer of endoemtrium, as well as for malignant diseases in general, it is necessary to always count on is the possibility of their rare presentation.
  • Management of cancer of endometrium is kept by oncogynecologist.
  • In line with the trend of reduction radical solution and subsequent complications of surgical oncological studies are conducted on the possibility of detection of sentinel nodes, which hinted at a lack of data and experience, a complicating factor is also relatively complicated lymphatic drainage, body of the uterus.
  • Research then turned to clarify the pathogenesis at the molecular level, the identification of new specific biomarkers that could help in early diagnosis and therapy.
  • In the context of inherited disposition cancer of endometrium is then appropriate to focus on the relevant risk group of patients with accumulation of cancer of endometrium and colorectal cancer in a personal and family history, which are then indicated to the genetic consultation and possibly mutation analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063843.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 26
  •  go-up   go-down


54. Risse EK, Ouwerkerk-Noordam E, Meijer-Marres EM, Boon ME: Exploiting the residual of cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies. Acta Cytol; 2010 Mar-Apr;54(2):175-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploiting the residual of cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies.
  • OBJECTIVE: To exploit cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies.
  • STUDY DESIGN: Fourteen cases from women with carcinoma diagnosed in 2006 were selected out of 29 invasive carcinomas.
  • Eight women had squamous cell carcinoma, 4 endocervical adenocarcinoma, 1 endometrial adenocarcinoma and 1 ovarian adenocarcinoma.
  • These were stained with the Papanicolaou method and for the biomarkers Ki-67 and p16 and, if desired, for differentiation markers, including carcinoembryonic antigen, vimentin, cytokeratin 7 and cytokeratin 20 to establish the immunoprofile of the carcinoma.
  • RESULTS: The morphologic details in the cancer nuclei in the paraffin sections were excellent, while in all cases the thin layer cytology slide contained thick epithelial fragments with blurred nuclei.
  • In 5 of the 6 adenocarcinomas, the glandular architecture diagnostic of adenocarcinoma was visible in the cytohistology, which was highlighted in the biomarker stainings, particularly so in the Ki-67 sections.
  • With the exception of endometrial adenocarcinoma, all p16(INK4a) stainings were positive, as they were in the ovarian adenocarcinoma case.
  • CONCLUSION: Cytohistology is an adjunct to routine cervical cytologic examination of thin layer samples, allowing an unequivocal and refined diagnosis.
  • [MeSH-major] Cytodiagnosis / methods. Immunohistochemistry / methods. Neoplasm, Residual / diagnosis. Uterine Cervical Neoplasms / diagnosis


55. Czeczuga-Semeniuk E, Wołczyński S: Dietary carotenoids in normal and pathological tissues of corpus uteri. Folia Histochem Cytobiol; 2008;46(3):283-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carotenoids and retinyl esters are the source of vitamin A in the human body and its natural derivatives takes part in the regulation of cell replication and differentiation in the human endometrium, may induce the leiomyoma growth and has a role in differentiation of endometrial adenocarcinoma.
  • The aim of the study was to demonstrate the presence of carotenoids in tissues from the normal uterus and from various tumors of the uterine corpus, as well as to compare the total content, major carotenoids and % of carotenoids belonging to the provitamin A group between the tissues examined.
  • In normal tissues, the mean carotenoid content was the highest in the follicular phase endometrium (9.9 microg/g), while the highest percentage of carotenoids belonging to provitamin A group was found in the luteal phase (18.2%).
  • In the pathological group, the highest mean values were demonstrated for epithelial lesions (8.0 microg/g), and within this group - in endometrioid adenocarcinoma (10.8 microg/g).
  • We have demonstrated that all uterine tissues show a concentration of beta-carotene and beta-cryptoxanthin, being the source of vitamin A.
  • The highest total values of carotenoids obtained in the group of endometrioid adenocarcinoma seem to confirm certain enzymatic defects in carotenoid metabolism in the course of the neoplastic process or some metabolic modifications.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056531.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Cryptoxanthins; 0 / Xanthophylls; 01YAE03M7J / beta Carotene; 36-88-4 / Carotenoids; 51C926029A / violaxanthin; KK8M5T48AI / neoxanthin; X72A60C9MT / Lutein
  •  go-up   go-down


56. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens. J Med Assoc Thai; 2008 Sep;91(9):1313-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens.
  • OBJECTIVE: To evaluate the hysterectomy specimen findings in the patients who underwent fractional curettage (F&C) with presence of adenocarcinoma in both endocervical and endometrial specimens.
  • MATERIAL AND METHOD: Forty-one patients who had adenocarcinoma in both endocervical and endometrial specimens from F&C and underwent subsequent hysterectomy for surgical staging without pre-operative radiotherapy or chemotherapy at King Chulalongkorn Memorial Hospital between 1999 and 2007 were evaluated Histologic slides from both F&C and hysterectomy specimens were reviewed and assessed All cases of endometrial adenocarcinoma with cervical involvement (stage 2) in hysterectomy specimens were also assessed and compared to the results in F&C specimens.
  • RESULTS: Fifteen patients (36.6%) with both positive endocervical and endometrial specimens from F&C were diagnosed as endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Only 34.1% of cases were endometrial carcinomas with cervical involvement.
  • In the 35 cases with endometrial carcinoma stage 2, 60% had adenocarcinoma in both endocervical and endometrial specimens from F&C.
  • CONCLUSION: In the patients who had adenocarcinoma in both endocervical and endometrial specimens from fractional curettage, the most common final pathological diagnosis from hysterectomy specimens was endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Therefore, only 60% of endometrial carcinoma stage 2 revealed positive adenocarcinoma in both endocervical and endometrial specimens from fractional curettage.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Dilatation and Curettage. Endometrial Neoplasms / pathology. Endometrium / pathology. Hysterectomy


57. Nofech-Mozes S, Rasty G, Ismiil N, Covens A, Khalifa MA: Immunohistochemical characterization of endocervical papillary serous carcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:286-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical characterization of endocervical papillary serous carcinoma.
  • Endocervical adenocarcinomas are rare and aggressive neoplasms.
  • Papillary serous endocervical adenocarcinomas are the rarest form of endocervical adenocarcinomas.
  • This tumor exhibits morphologic similarities to its counterparts commonly seen in the endometrium, fallopian tubes, ovaries, and peritoneum, which are known to have an aggressive behavior.
  • In this study, we included ten cases of papillary serous carcinomas arising from the uterine cervix (PSCC) diagnosed in the absence of a primary endometrial malignancy.
  • We studied their immunohistochemical profile, using a panel of antibodies against Ki67, bcl-2, p53, carcinoembryonic antigen (CEA), and CD10, and compared them to 20 consecutive cases of cervical adenocarcinoma of conventional cell subtypes (CAC) (15 mucinous, 3 adenosquamous, and 2 endometrioid).
  • PSCC is a distinctive immunophenotypic subtype of endocervical adenocarcinoma with significantly higher p53 and lower CEA reactivity than other more common histologic subtypes.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Biomarkers, Tumor / biosynthesis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515605.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


58. Zhou J, Shen K, Zeng JF, Yang JX, Cao DY, Cui QC: [Differential expression of microRNAs associated with estrogen receptor alpha and progesterone receptor in typeIand typeII endometrial adenocarcinomas.]. Zhonghua Fu Chan Ke Za Zhi; 2009 Oct;44(10):765-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential expression of microRNAs associated with estrogen receptor alpha and progesterone receptor in typeIand typeII endometrial adenocarcinomas.].
  • OBJECTIVE: To identify differentially expression of microRNAs associated with expression of estrogen receptor alpha (ERalpha) and progesterone receptor (PR) between type I and type II endometrial adenocarcinoma.
  • METHODS: Two kinds of endometrial adenocarcinoma cell lines, Ishikawa and KLE, was transplanted into nude mice and biopsied to identify the expression of ERalpha, PR and p53, and test their response to estrogen and progesterone.
  • RESULTS: Ishikawa cell line was confirmed from type I endometrial adenocarcinoma, KLE cell line was confirmed from type II endometrial adenocarcinoma.
  • CONCLUSION: Hsa-miR-100 is significantly down-expressed in type I endometrial adenocarcinoma compared to type II, which may be a great potential to target ESR1.
  • [MeSH-minor] Adenocarcinoma / genetics. Animals. Endometrial Neoplasms. Estrogen Receptor alpha / metabolism. Gene Expression Regulation, Neoplastic. Humans. Mice, Nude

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078964.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / MicroRNAs; 0 / Receptors, Progesterone
  •  go-up   go-down


59. Sales KJ, Maldonado-Pérez D, Grant V, Catalano RD, Wilson MR, Brown P, Williams AR, Anderson RA, Thompson EA, Jabbour HN: Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Biochim Biophys Acta; 2009 Dec;1793(12):1917-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway.
  • Recently we showed elevated expression of the chemokine (C-X-C motif) receptor 2 (CXCR2) in endometrial adenocarcinomas localized to neutrophils and neoplastic epithelial and vascular cells.
  • Furthermore we found that PGF(2alpha)-F-prostanoid (FP) receptor regulates the expression of the CXCR2 ligand CXCL1, to promote neutrophil chemotaxis in endometrial adenocarcinomas.
  • In the present study we identified another CXCR2 ligand, CXCL8 as a target for PGF(2alpha)-FP receptor signalling which enhances epithelial cell proliferation in endometrial adenocarcinoma cells in vitro and in nude mice in vivo.
  • We found that PGF(2alpha)-FP receptor interaction induces CXCL8 expression in endometrial adenocarcinoma cells via the protein kinase C-calcium-calcineurin-NFAT signaling pathway.
  • Using an adenovirus to overexpress RCAN1-4, we found that RCAN1-4 is a negative regulator of CXCL8 expression in endometrial adenocarcinoma cells.
  • Taken together our data have elucidated the molecular and cellular mechanism whereby PGF(2alpha) regulates CXCL8 expression via the FP receptor in endometrial adenocarcinomas and have highlighted RCAN1-4 as a negative regulator of CXCL8 expression which may be exploited therapeutically to inhibit CXCL8-mediated tumour development.
  • [MeSH-major] Adenocarcinoma / metabolism. Calcineurin / metabolism. Calcium / metabolism. Endometrial Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Interleukin-8 / biosynthesis. NFATC Transcription Factors / metabolism. Neoplasm Proteins / metabolism. Receptors, Prostaglandin / metabolism. Signal Transduction

  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2373-80 [17893866.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3023-8 [17595344.001]
  • [Cites] Cytokine. 2008 Mar;41(3):232-9 [18182303.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):51-61 [18316157.001]
  • [Cites] Oral Oncol. 2008 Oct;44(10):920-6 [18282785.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1793(7):1315-24 [19348862.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5726-33 [19549892.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1221-36 [10582349.001]
  • [Cites] J Immunol. 2000 Jun 1;164(11):5944-51 [10820277.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):357-64 [11162945.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4893-8 [11320240.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21797-808 [11259418.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2476-89 [11402342.001]
  • [Cites] Oncogene. 2001 May 17;20(22):2771-80 [11420689.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] Am J Reprod Immunol. 2002 Apr;47(4):213-21 [12069388.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):125-34 [12107097.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Reproduction. 2003 Nov;126(5):559-67 [14611628.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1030-43 [15057743.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7554-9 [15131267.001]
  • [Cites] Bioorg Med Chem. 2004 Jun 15;12(12):3125-33 [15158780.001]
  • [Cites] Trends Endocrinol Metab. 2004 Oct;15(8):398-404 [15380812.001]
  • [Cites] J Cell Physiol. 1986 Dec;129(3):375-84 [3465735.001]
  • [Cites] J Pharmacol Exp Ther. 1990 Nov;255(2):756-68 [2147038.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):1-16 [2026352.001]
  • [Cites] Cancer Surv. 1994;19-20:287-307 [7895220.001]
  • [Cites] J Biol Chem. 1995 Jun 16;270(24):14255-8 [7782278.001]
  • [Cites] Biol Chem Hoppe Seyler. 1996 Jun;377(6):373-84 [8839983.001]
  • [Cites] J Biol Chem. 1996 Oct 25;271(43):27018-24 [8900190.001]
  • [Cites] Chem Biol. 1996 Dec;3(12):981-91 [9000009.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Dec;70(1):15-7 [9031912.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):4919-24 [9144165.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1201-5 [9543141.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10095-8 [9553055.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1783-7 [9589693.001]
  • [Cites] Hum Reprod. 1998 Aug;13(8):2292-5 [9756313.001]
  • [Cites] Mol Endocrinol. 1999 Feb;13(2):276-85 [9973257.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2435-8 [10051660.001]
  • [Cites] Gastroenterol Clin North Am. 1999 Jun;28(2):459-77, x [10372277.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84 [10454504.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47438-45 [15339913.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50537-54 [15448146.001]
  • [Cites] Hum Reprod. 2005 Mar;20(3):794-801 [15618253.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13075-80 [16131541.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4198-207 [16618742.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):1039-52 [18045955.001]
  • (PMID = 19819266.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / IL8 protein, human; 0 / Interleukin-8; 0 / NFATC Transcription Factors; 0 / Neoplasm Proteins; 0 / Receptors, Prostaglandin; 0 / prostaglandin F2alpha receptor; B7IN85G1HY / Dinoprost; EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.16 / Calcineurin; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2806519
  •  go-up   go-down


61. Koshiba H, Hosokawa K, Kubo A, Tokumitsu N, Watanabe A, Honjo H: Junctional adhesion molecule A [corrected] expression in human endometrial carcinoma. Int J Gynecol Cancer; 2009 Feb;19(2):208-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Junctional adhesion molecule A [corrected] expression in human endometrial carcinoma.
  • Loss of cell adhesion molecules may be associated with high histologic grade and invasiveness of endometrial carcinoma.
  • We attempted to determine JAM-A expression in human endometrial carcinoma and its correlations with pathologic features, stage, and survival.
  • Junctional adhesion molecule A expression in human endometrial carcinoma was evaluated by immunohistochemistry.
  • In addition, we cultured human well and poorly differentiated endometrial adenocarcinoma cell lines, Ishikawa cells, and KLE in 3-dimensional basement membrane preparation, and JAM-A expression in these cells was assessed by real-time reverse transcription-polymerase chain reaction and immunohistochemistry.
  • Additionally, in our 3-dimensional epithelial cell culture, JAM-A expression in poorly differentiated adenocarcinoma was significantly lower than that in well-differentiated adenocarcinoma (P < 0.001).
  • Junctional adhesion molecule A expression seems to be reduced in high-grade or advanced endometrial carcinoma and may be a prognostic factor.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Endometrial Neoplasms / metabolism. Immunoglobulins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Cancer. 2009 Aug;19(6):1153
  • (PMID = 19395995.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / F11R protein, human; 0 / Immunoglobulins; 0 / Receptors, Cell Surface
  •  go-up   go-down


62. Hanley KZ, Tadros TS, Briones AJ, Birdsong GG, Mosunjac MB: Hematologic malignancies of the female genital tract diagnosed on liquid-based Pap test: Cytomorphologic features and review of differential diagnoses. Diagn Cytopathol; 2009 Jan;37(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical symptoms are often nonspecific and mimic other more common gynecologic malignancies such as squamous cell carcinoma of the cervix or endometrial adenocarcinoma.
  • Although cervico-vaginal (Pap) smear is the primary screening method for cervical squamous cell carcinoma and its precursors, it is far less sensitive for detection of other primary or metastatic malignancies.
  • In this review, we present three cases of hematologic gynecologic malignancies, two cases of primary NHL, and a case of acute myeloid leukemia with relapse as a pelvic mass, all of which were diagnosed on a liquid-based Pap test.
  • In addition, we discuss the morphologic features of differential diagnostic entities of these rare tumors on conventional and liquid-based preparations.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Papanicolaou Test. Vaginal Smears


63. Lehmann L, Wagner J, Metzler M: Estrogenic and clastogenic potential of the mycotoxin alternariol in cultured mammalian cells. Food Chem Toxicol; 2006 Mar;44(3):398-408
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AOH replaced E2 from isolated human estrogen receptors alpha and beta and increased the level of alkaline phosphatase (ALP) mRNA and the enzymatic activity of ALP in a human endometrial adenocarcinoma cell line (Ishikawa cells).
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / metabolism. Alternaria / metabolism. Animals. Cell Line, Tumor. Chromosome Aberrations. Cricetinae. Cricetulus. Dose-Response Relationship, Drug. Endometrial Neoplasms / enzymology. Endometrial Neoplasms / metabolism. Enzyme Induction. Esophageal Neoplasms / chemically induced. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Female. Flow Cytometry. Food Contamination. Humans. Male. Micronucleus Tests. RNA, Messenger / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194592.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholinesterase Inhibitors; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Lactones; 0 / Mutagens; 0 / RNA, Messenger; EC 3.1.3.1 / Alkaline Phosphatase; KN9L4260JW / alternariol
  •  go-up   go-down


64. Hecht JL, Dolinski BM, Gardner HA, Violette SM, Weinreb PH: Overexpression of the alphavbeta6 integrin in endometrial cancer. Appl Immunohistochem Mol Morphol; 2008 Dec;16(6):543-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the alphavbeta6 integrin in endometrial cancer.
  • The alpha(v)beta(6) integrin (alphavbeta6) has been shown to be up-regulated in adenocarcinoma of the breast, colon, stomach, and ovary, generally reflecting a more aggressive phenotype.
  • Expression in endometrial cancer has not been reported.
  • We analyzed alphavbeta6 expression in the tissue from primary endometrial carcinomas (endometrioid type) using a mouse monoclonal antibody against human alphavbeta6, and correlated the findings with grade, stage, and nodal involvement.
  • Normal cycling endometrium was studied for comparison. alphavbeta6 was only weakly expressed in normal epithelium and infrequently expressed in precancers, but up-regulated in the majority of endometrial carcinomas, especially with high grade.
  • Overexpression of alphavbeta6 in endometrial carcinoma is common.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698261.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaV; 0 / Integrin beta Chains; 0 / integrin beta6
  •  go-up   go-down


65. Zhang SQ, Cai B, Liu L, He YY, Yang YX, Wan XP: Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway. Int J Gynecol Cancer; 2009 Nov;19(8):1377-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.
  • OBJECTIVE: The aim of this study was to investigate the expression of kallikrein 4 (KLK4) and the potential signal pathway through which estrogen up-regulates KLK4 in endometrial cancer.
  • METHODS: The expression of KLK4 was analyzed in 15 human normal endometrium, 13 hyperplasia endometrium, and 68 endometrioid adenocarcinoma by immunohistochemistry.
  • After exposure to 17beta-estradiol and/or to the mitogen-activated protein kinase (MAPK) inhibitor U0126 and to the PI3K inhibitor LY294002, the expression of KLK4 in the endometrial cancer cell lines KLE and RL95-2 was detected with quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and Western blot.
  • RESULTS: The expression of KLK4 protein was higher in endometroid endometrial cancer than in hyperplasia or normal endometrium (P < 0.001).
  • Immunohistochemical staining revealed that 92.6% (63/68) of endometrial adenocarcinoma, 61.5% (8/13) of hyperplasia endometrium, and 26.7% (4/15) of normal endometrium were positive for KLK4 protein.
  • Quantitative reverse transcriptase PCR and Western blot analysis showed that estrogen can up-regulate the expression of KLK4 in endometrial cancer cell lines KLE and RL95-2, and the up-regulation effect of 17beta-estradiol on KLK4 can be inhibited by U0126 in the 2 endometrial cancer cell lines but not by LY294002.
  • CONCLUSIONS: Kallikrein 4 is a new nuclear protein, and estrogen up-regulates the expression of KLK4 by activating the MAPK pathway in endometrial cancer cell lines, which may play an important role in the development of endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Estradiol / pharmacology. Kallikreins / metabolism. Mitogen-Activated Protein Kinases / metabolism

  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009893.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4
  •  go-up   go-down


66. Li ZL, Morishima S, Tang JT, Otsuki Y: Apoptotic effects of Tian-Long compound on endometrial adenocarcinoma cells in vitro. Med Mol Morphol; 2009 Mar;42(1):32-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic effects of Tian-Long compound on endometrial adenocarcinoma cells in vitro.
  • To explore its antitumor properties and the mechanism for activity in gynecological malignancies, the present studies were carried out using Ishikawa cells derived from uterine endometrial adenocarcinoma.
  • The present results indicate that the ingredients of TL compound are very promising for use in the treatment of endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Drugs, Chinese Herbal / pharmacology. Endometrial Neoplasms / drug therapy. Phytotherapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Rev Cytol. 1980;68:251-306 [7014501.001]
  • [Cites] J Histochem Cytochem. 2003 Dec;51(12):1601-9 [14623928.001]
  • [Cites] J Nat Prod. 2001 Mar;64(3):286-8 [11277740.001]
  • [Cites] Med Mol Morphol. 2008 Mar;41(1):34-43 [18470679.001]
  • [Cites] Cell Stress Chaperones. 1998 Dec;3(4):213-20 [9880233.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2133-9 [8481916.001]
  • [Cites] Am J Chin Med. 1994;22(2):137-45 [7992813.001]
  • [Cites] Food Chem Toxicol. 2003 Oct;41(10 ):1421-8 [12909277.001]
  • [Cites] Pathol Annu. 1982;17 Pt 2:229-59 [7182752.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):327-32 [15251124.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1456-62 [7878464.001]
  • [Cites] Med Mol Morphol. 2008 Sep;41(3):132-8 [18807138.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):5870-8 [2790800.001]
  • [Cites] Lancet. 1994 Jul 2;344(8914):28-9 [7912299.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:150-6 [15650241.001]
  • [Cites] J Leukoc Biol. 1993 Nov;54(5):407-13 [8228619.001]
  • [Cites] Biochem Syst Ecol. 2000 Jun 1;28(5):403-419 [10725598.001]
  • [Cites] J Ethnopharmacol. 1999 Nov 1;67(2):163-9 [10619380.001]
  • [Cites] World J Gastroenterol. 2003 Sep;9(9):1963-7 [12970885.001]
  • [Cites] Toxicol Appl Pharmacol. 1994 Oct;128(2):169-81 [7940532.001]
  • [Cites] J Pharmacobiodyn. 1990 Jul;13(7):426-31 [2290126.001]
  • [Cites] Hum Cell. 2002 Sep;15(3):104-17 [12703541.001]
  • (PMID = 19294490.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Neoplasm; 0 / Drugs, Chinese Herbal; 0 / Phosphatidylserines; 0 / Proto-Oncogene Proteins c-bcl-2; 4TI98Z838E / Estradiol; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


67. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC: The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol; 2007 Apr;196(4):402.e1-10; discussion 402.e10-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
  • OBJECTIVE: To examine the effects of metformin and rosiglitazone, alone and in combination, on endometrial histology and ovarian steroid production.
  • RESULTS: Abnormal endometrial histology was found in 3 subjects at baseline, including 1 case of adenocarcinoma of the endometrium in an asymptomatic subject, who was excluded from further study.
  • CONCLUSION: This study provides preliminary evidence that insulin-sensitizing drugs may have beneficial effects on the endometrium, although the exact mechanism beyond improving ovulatory function is still unknown.
  • [MeSH-major] Endometrium / pathology. Metformin / therapeutic use. Ovary / pathology. Polycystic Ovary Syndrome / drug therapy. Thiazolidinediones / therapeutic use

  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403436.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR016499; United States / NICHD NIH HHS / HD / K24 HD001476; United States / NCRR NIH HHS / RR / M01 RR010732
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; 9100L32L2N / Metformin
  •  go-up   go-down


68. Ioffe OB: Recent developments and selected diagnostic problems in carcinomas of the endometrium. Am J Clin Pathol; 2005 Dec;124 Suppl:S42-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments and selected diagnostic problems in carcinomas of the endometrium.
  • Two major types of endometrial carcinoma have been well described as differing not only in their pathogenesis but also in their behavior, therefore requiring different management.
  • These implications make the differential diagnosis between the 2 pathogenetic types, specifically their prototypes, endometrioid and serous endometrial carcinomas, paramount.
  • However, this differential diagnosis may be difficult owing to overlapping histologic features such as papillary architecture.
  • To that end, the differential diagnosis of endometrial tumors with papillary morphologic features is discussed in detail.
  • Preinvasive and early invasive serous carcinoma (endometrial intraepithelial carcinoma and minimal serous carcinoma) have been claimed to have a good prognosis if accurate staging confirmed lack of extrauterine spread.
  • In addition, several recently described variants and histologic patterns of endometrial carcinoma that might present diagnostic problems, such as microglandular mucinous carcinoma, sertoliform carcinoma, carcinoma arising in an atypical polypoid adenomyoma, and endometrial carcinoma with a minimal deviation adenocarcinoma pattern of myoinvasion, are described.
  • [MeSH-major] Endometrial Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Biopsy. Cell Proliferation. Diagnosis, Differential. Endometrium / pathology. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468417.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


69. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, Cho KR, Copeland L, Crispens MA, Eifel PJ, Huh WK, Jaggernauth W, Kapp DS, Kavanagh JJ, Lurain JR 3rd, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Alvarez Secord A, Small W Jr, Teng N: Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw; 2009 May;7(5):498-531
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine Neoplasms. Clinical Practice Guidelines in Oncology.
  • [MeSH-major] Adenocarcinoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Brachytherapy. Combined Modality Therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Endometrium / pathology. Evidence-Based Medicine. Female. Hormone Replacement Therapy. Humans. Hysterectomy. Myometrium / pathology. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460278.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


70. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y, Feng Y: Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer; 2006 Aug 15;107(4):746-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
  • BACKGROUND: Endometrial cancer is a common gynecologic malignancy among women.
  • The molecular mechanisms involved in the progression of endometrial cancer are unclear, which has hampered the development of an effective treatment.
  • METHODS: Survivin mRNA and protein expression levels were analyzed in human normal cycling endometrium, atypical endometrium, and endometrial adenocarcinoma by immunohistochemical, reverse-transcriptase polymerase chain reaction (RT-PCR), and Western blot analyses.
  • To study the biological function of survivin in endometrial cancer, RNA interference was applied to knock down survivin expression in the Ishikawa endometrial cancer cell line by recombinant plasmids producing survivin small hairpin RNA.
  • RESULTS: Higher levels of survivin mRNA and protein expression were observed in endometrial adenocarcinomas than in atypical or normal endometrium.
  • Immunohistochemical staining revealed that 83.3% (50 of 60) of endometrial adenocarcinoma samples, 55.0% (11 of 20) of atypical endometrium samples, and 25.0% (5 of 20) of normal endometrium samples were positive for survivin protein.
  • Epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) upregulated survivin protein expression by activating the MAPK pathway in endometrial cancer cells.
  • CONCLUSIONS: Survivin is an attractive target for endometrial cancer treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cell Proliferation. Endometrial Neoplasms / pathology. Microtubule-Associated Proteins / antagonists & inhibitors. Neoplasm Proteins / antagonists & inhibitors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826583.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Cysteine Proteinase Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


71. Chen F, Shen K, Lang JH, Huang HF, Wu M: [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary]. Zhonghua Yi Xue Za Zhi; 2005 May 18;85(18):1257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary].
  • OBJECTIVE: To investigate the clinical features, treatment and prognosis of patients with double primary carcinoma of uterine corpus and ovary.
  • METHODS: The clinical features, operation findings, treatment and prognosis of 36 patients with double primary carcinoma of uterine corpus diagnosed and treated in the last 20 years, 25 with typical endometrial adenocarcinoma and endometrioid carcinoma of the ovary (group A) 11 with non-endometrioid carcinoma in uterine corpus and/or ovary (group B) were respectively analyzed.
  • RESULTS: There was no significant difference in survival rate between the group A and group B.
  • The 1, 3, and 5-year survival rates of these 36 patients were 89%, 83%, and 75% respectively, all equal to those of the patients with stage I ovarian cancer.
  • CONCLUSION: The prognosis of double primary carcinoma of uterine corpus and ovary is rather good.
  • It is necessary to distinguish double primary carcinoma of uterine corpus and ovary from stage II ovarian cancer and stage III endometrial carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029611.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


72. Wu HM, Lai CH, Huang HY, Wang HS, Soong YK: A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer. Chang Gung Med J; 2008 Jan-Feb;31(1):102-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer.
  • Endometrial cancer is predominately a postmenopausal disease.
  • Endometrial cancer in women of childbearing age is relatively unusual.
  • Endometrial cancer is typically treated with hysterectomy.
  • After the development of endometrial cancer, successful pregnancy is rare.
  • We present a case of recurrent stage I endometrial adenocarcinoma in a 35-year-old woman.
  • Magnetic resonance imaging (MRI) revealed endometrial lesions without myometrium invasion and no pelvic lymph node enlargement.
  • On the basis of these observations and the low malignant potential of well-differentiated endometrial carcinoma, fertility-preserving treatment using Megace therapy was suggested.
  • Recurrent endometrial adenocarcinoma was documented using hysteroscopy and direct endometrial biopsy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Fertilization in Vitro. Megestrol Acetate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Twins

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419059.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


73. Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, Fischer AH: Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol; 2007 Dec;20(12):1263-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
  • Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is a newly identified oncofetal mRNA-binding protein that is involved in embryogenesis and carcinogenesis of some malignant neoplasms.
  • To investigate the diagnostic and clinicopathologic significance of this protein in endometrial carcinomas, we evaluated immunohistochemical expression of IMP3 in the two most common forms of endometrial malignancies, endometrioid adenocarcinoma and serous carcinoma.
  • We selected 167 endometrial adenocarcinoma cases including 122 cases of endometrioid adenocarcinoma and 45 cases of serous carcinoma.
  • Twenty samples of benign endometrium obtained from 20 patients with nonmalignant uterine lesions were used as controls.
  • Positive immunohistochemical stain for IMP3 was identified in all serous carcinoma cases, among which, 39 (86%) and 3 (7%) cases showed IMP3 immunoreactivity in >50%, and 21-50, or 6-20% of tumor cells, respectively.
  • Immunohistochemical reaction intensity for IMP3 was identified to be strong in 38 (84%) and intermediate in 7 (16%) cases of serous carcinoma.
  • Fifty-four (44%) cases of endometrioid adenocarcinoma were negative for IMP3.
  • Thirty (25%), 20 (16%), 10 (8%), and 8 (7%) cases of endometrioid adenocarcinoma demonstrated positive immunoreactivity for IMP3 in 1-5, 6-20, 21-50, and >50% of the tumor cells.
  • Strong IMP3-staining intensity was noted in 34 (28%), intermediate in 26 (21%), and weak in 8 (7%) cases of endometrioid adenocarcinoma.
  • To compare p53 with IMP3 expressions, we found that 35 (78%) of the serous carcinoma cases showed strong p53 immunohistochemical activity in >50% of the tumor cell nuclei.
  • In contrast, 11 of 112 (10%) endometrioid adenocarcinoma cases demonstrated strong p53 positivity in >50% of the tumor cell nuclei.
  • In conclusion, our findings demonstrate significant expression of IMP3 in serous carcinoma as compared to endometrioid adenocarcinoma (P<0.0001).
  • Expression of IMP3 and p53 may be helpful biomarkers in the distinction of endometrial serous carcinoma from endometrioid adenocarcinoma.
  • In addition, expression of IMP3 in endometrioid adenocarcinoma correlates with higher nuclear and architecture grades of the tumor (P=0.0000 and P=0.0002, respectively).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / biosynthesis. Diagnosis, Differential. Female. Gene Expression. Humans. Immunohistochemistry. Middle Aged. Tumor Suppressor Protein p53 / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885673.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / oncofetal antigens
  •  go-up   go-down


74. Indraccolo U, Cingolani N, Indraccolo SR: Bilateral Brenner tumor with endometrial adenocarcinoma in a postmenopausal woman. Eur J Gynaecol Oncol; 2007;28(3):233-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral Brenner tumor with endometrial adenocarcinoma in a postmenopausal woman.
  • Brenner tumor is a rare ovarian neoplasm which is generally monolateral, more rarely bilateral, and often associated with endometrial disorders related to oestrogenic production.
  • However, there is no considerable evidence that the possible oestrogenic production of this tumor may be the cause of endometrial disorders.
  • A case of bilateral Brenner tumor with endometrial adenocarcinoma in a postmenopausal woman is presented and the features are briefly discussed, with the conclusion that hormone-producing Brenner tumors may exert their promoter effect on the development of endometrial carcinoma causing an imbalance in the oestrogen and progesterone ratio rather than producing a large amount of oestrogen.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Endometrioid / pathology. Endometrial Stromal Tumors / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Postmenopause

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624095.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


76. Buccoliero AM, Resta L, Napoli A, Taddei GL: Liquid-based endometrial cytology: the Florence and Bari experience. Pathologica; 2009 Apr;101(2):80-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liquid-based endometrial cytology: the Florence and Bari experience.
  • Several diagnostic procedures are available to investigate the endometrium, i.e. sonography, hysteroscopy, biopsy, endometrial curettage and cytology.
  • Among these, endometrial cytology is less commonly utilized.
  • Although the use of cytology in the diagnosis of endometrial adenocarcinoma has already been proposed due to its low cost and simple execution, a general consensus has not been reached.
  • The improvement of the diagnostic capacity of endometrial cytology following the introduction of a liquid-based method suggests that this test should be routinely used in endometrial diagnosis.
  • The aim of this article is to focus on the methodological procedures and diagnostic criteria in liquid-based endometrial cytology based on the experience in two Italian centres: Department of Pathology, University of Bari and Department of Human Pathology and Oncology, University of Florence.
  • The sampling method used by the Bari authors consists in the collection of liquid for uterine distension during hysteroscopy, while the Florence group used an endometrial brush.
  • Endometrial cytology provided sufficient diagnostic material significantly more often than biopsy.
  • We thus propose that endometrial cytology can be used in routine diagnosis either alone or in association with other diagnostic procedures in order to improve diagnostic accuracy.
  • [MeSH-major] Cytological Techniques / methods. Endometrium / pathology. Uterine Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886553.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


77. Krepinska E, Kriz JT, Laco J: Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman. Eur J Gynaecol Oncol; 2010;31(5):584-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • Synchronous primary cancers of the endometrium and ovary occur in approximately 10% of all women with ovarian cancer and 5% of all women with endometrial cancer.
  • The pathogenesis of synchronous endometrial and ovarian cancer is unclear.
  • We report a case of unusual co-existence of endometroid adenocarcinoma of the uterus, serous borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061809.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


78. Maxwell GL, Tian C, Risinger J, Brown CL, Rose GS, Thigpen JT, Fleming GF, Gallion HH, Brewster WR, Gynecologic Oncology Group study: Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer; 2006 Nov 1;107(9):2197-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.
  • BACKGROUND: Previous studies have reported shorter survival of black women compared with white women who had advanced/recurrent endometrial cancer.
  • METHODS: The authors retrospectively reviewed data from 169 black women and 982 white women with International Federation of Gynecologic Oncology (FIGO) Stage III, Stage IV, or recurrent endometrial carcinoma who were participants in 1 of 4 Gynecologic Oncology Group randomized treatment trials of doxorubicin alone or combined with paclitaxel and/or cisplatin.
  • CONCLUSIONS: The data from a large group of women with advanced/recurrent endometrial cancer suggested that a racial disparity in survival persists, despite the finding that black women and white women received similar treatment.
  • Although the causes of racial disparity in endometrial cancer remain to be elucidated, socioeconomic, biologic, and cultural factors should be investigated to identify the etiologic origins of this multifactorial healthcare problem.
  • [MeSH-major] Adenocarcinoma / ethnology. African Americans. Endometrial Neoplasms / ethnology. European Continental Ancestry Group. Neoplasm Recurrence, Local / ethnology

  • MedlinePlus Health Information. consumer health - African American Health.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001661.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


79. Xiong Y, Dowdy SC, Gonzalez Bosquet J, Zhao Y, Eberhardt NL, Podratz KC, Jiang SW: Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol; 2005 Oct;99(1):135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.
  • OBJECTIVES: To determine if epigenetic interference can restore progesterone receptor-B (PR-B) expression in PR-B negative endometrial adenocarcinoma cell lines, and to characterize the kinetics of PR-B induction mediated by DNA methyltransferase and histone deacetylase inhibitors.
  • METHODS: The PR-B negative endometrioid cancer cell lines KLE and HEC-1B were used as study models.
  • CONCLUSION: The epigenetically silenced PR-B gene remains sensitive to changes in DNA demethylation and histone acetylation in uterine adenocarcinoma cell lines.
  • These small molecule epigenetic modifying agents may be used to sensitize poorly differentiated, PR-B negative endometrial cancers to progestational therapy.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Receptors, Progesterone / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024066.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 0 / progesterone receptor B; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; EC 3.5.1.98 / Histone Deacetylases; M801H13NRU / Azacitidine
  •  go-up   go-down


80. Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR: Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol; 2006 Nov;103(2):684-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
  • OBJECTIVE: Uterine mixed malignant mullerian tumors (MMMT) have traditionally been excluded from clinical trials of endometrial cancer because of a belief that they are more correctly included in the sarcoma category.
  • Recently, investigators have suggested that uterine MMMTs are actually dedifferentiated epithelial tumors and should be treated as such.
  • The current study was undertaken to compare outcomes, stage for stage, of uterine MMMT with poor prognosis endometrial adenocarcinomas.
  • Cases were matched by age, stage, performance status, and surgical procedure to controls consisting of grade 3 endometrioid, papillary serous, and clear cell endometrial carcinomas from the same time period.
  • Of the controls, 31 (69%) had grade 3 endometrioid, 11 (24%) papillary serous, and 3 (7%) clear cell carcinoma.
  • CONCLUSIONS: Patients with uterine MMMT have a poorer prognosis than those patients with high grade epithelial tumors, especially for those with early stage disease.
  • Given the discrepancy in survival, these patients should not be included in studies of endometrial carcinoma.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Mixed Tumor, Mullerian / pathology. Mixed Tumor, Mullerian / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Case-Control Studies. Chemotherapy, Adjuvant. Female. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies


81. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in the female genital tract and its value in diagnosis.
  • Most cervical carcinomas of squamous, glandular, and small cell type are p16-positive.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • Some uterine serous carcinomas are diffusely positive.
  • Similarly, HPV-associated invasive squamous carcinomas are p16-positive, whereas the more common non-HPV-associated neoplasms are largely negative or focally positive.
  • In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied.
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • Some ovarian serous carcinomas, similar to their uterine counterparts, are p16-positive.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Genital Neoplasms, Female / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


82. Li HW, Leung SW, Chan CS, Yu MM, Wong YF: Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep; 2007 Feb;17(2):393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of maspin in endometrioid adenocarcinoma of endometrium.
  • Underexpression of maspin has been reported in breast and prostatic cancers, but in some cancers such as ovarian, colorectal and pancreatic carcinoma, it was found to be up-regulated.
  • This study aimed at demonstrating the expression of maspin in human endometrial tissue and searching for any altered expression in endometrioid adenocarcinoma of the endometrium compared to normal endometrium.
  • The expression level of the maspin gene was studied using reverse transcriptase-polymerase chain reaction (RT-PCR) performed on RNA extracted from 34 endometrial cancer samples (including 24 with FIGO stage I disease and 10 with FIGO stage III disease) and 28 normal endometrium in proliferative or secretory phases.
  • Immunohistochemical staining was also performed on 10 cases of endometrial cancer (6 FIGO stage I cases and 4 FIGO stage III cases) as well as 15 normal endometrium.
  • Semi-quantitative RT-PCR revealed that the expression of maspin was significantly up-regulated in both stage I (p<0.01) and stage III (p<0.01) endometrial cancer compared with normal endometrium.
  • However, no significant difference in maspin expression was demonstrated between stage I and stage III endometrial cancer.
  • Immunostaining of all tissue sections revealed an immunopositive signal in the nuclei of the normal or cancerous endometrial glandular cells.
  • In 60% of the cancer cases, cytoplasmic staining was also evident.
  • Our results suggested that there is up-regulated expression of maspin in endometrioid endometrial adenocarcinoma.
  • Cytoplasmic immuno-expression of maspin is common in endometrial cancer.
  • It may play a role in the malignant transformation of human endometrial tissue.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Gene Expression Regulation, Neoplastic. Serpins / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203179.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


83. Dai FR, Peng GQ, Zhang Y, Chen CX: [Clinical observation of young, middle-aged and elderly women with endometrial carcinoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Dec;30(6):690-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation of young, middle-aged and elderly women with endometrial carcinoma].
  • OBJECTIVE: To explore the clinical features, diagnosis, treatment and prognosis of endometrial carcinoma in young, middle-aged and elderly women.
  • METHODS: We retrospectively analyzed the clinical data of 82 cases of endometrial carcinoma in young, middle-aged women and 33 cases of endometrial cacinoma in elderly women.
  • RESULTS: The rates of adenocarcinoma in young, middle-aged and elderly groups were 74.4% and 75.5%, respectively.
  • The young,middle-aged and elderly patients with Stage I endometrial cancer were 64.6% and 69.7%, and those with Stage III and IV were 15.9% and 15.2%, respectively.
  • The histological Grade 1 carcinoma of endometrium in young,middle-aged and elderly women were 70.7% and 60.6%, respectively.
  • CONCLUSION: Adenocarcinoma and well-differentiated cells are the main pathological characteristics of endometrial carcinoma both in the young, middle-aged and the elderly women.
  • Early diagnosis and reasonable treatment can improve the prognosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708811.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


84. Liao CL, Hsu JD, Lee MY, Kok LF, Li YJ, Wang PH, Yao CC, Han CP: Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough? Virchows Arch; 2010 Apr;456(4):377-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough?
  • Gynecological pathologists are used to operating many panels of various markers in combination for the diagnostic distinction between primary endocervical and endometrial adenocarcinomas.
  • A tissue microarray was constructed using paraffin-embedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 primary endocervical adenocarcinomas and 21 primary endometrial adenocarcinomas.
  • However, one panel of 2-markers (Vim, CEA) exhibited the most efficiency (78.3%) in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas.
  • Based on the analyzed data, we conclude that the 2-marker (Vim/CEA) panel seems adequate to be an appropriate, convenient, and efficient means to distinguish between primary endocervical and endometrial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Endometrial Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vimentin / metabolism
  • [MeSH-minor] Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Protein Array Analysis / methods. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):974 [15223971.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):217-23 [12068166.001]
  • [Cites] J Exp Clin Cancer Res. 2008 Aug 02;27:25 [18673574.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Int J Gynecol Pathol. 2009 Sep;28(5):489-96 [19696622.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):402-23 [18318583.001]
  • [Cites] Arch Gynecol Obstet. 2009 Sep;280(3):405-13 [19153755.001]
  • [Cites] BMC Clin Pathol. 2006 Jan 12;6:1 [16409624.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):797-806 [19347018.001]
  • [Cites] Radiology. 2002 May;223(2):410-6 [11997546.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):271-7 [12647218.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] Virchows Arch. 2009 Oct;455(4):353-61 [19763614.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1091-100 [16648864.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] Arch Gynecol Obstet. 2010 May;281(5):845-50 [19847454.001]
  • [Cites] Curr Treat Options Oncol. 2004 Apr;5(2):119-27 [14990206.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):431-6 [18580323.001]
  • [Cites] Adv Anat Pathol. 2004 May;11(3):162-71 [15096730.001]
  • [Cites] J Transl Med. 2008 Jun 17;6:31 [18559092.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):160-7 [15043304.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):172-7 [8617459.001]
  • [Cites] J Negat Results Biomed. 2007 Apr 25;6:6 [17459164.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):4-10 [11781516.001]
  • (PMID = 20221633.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


85. Pejić S, Kasapović J, Todorović A, Stojiljković V, Pajović SB: Lipid peroxidation and antioxidant status in blood of patients with uterine myoma, endometrial polypus, hyperplastic and malignant endometrium. Biol Res; 2006;39(4):619-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid peroxidation and antioxidant status in blood of patients with uterine myoma, endometrial polypus, hyperplastic and malignant endometrium.
  • In this study, we explored the lipid peroxidation levels and antioxidant enzyme activities in women diagnosed with different forms of uterine diseases in order to evaluate the extent of oxidative stress in blood of such patients.
  • The results show that alterations of measured parameters vary with the enzyme type and diagnosis.
  • In addition, the lipid hydroperoxides/ glutathione peroxidase ratio was found to be increased, according to the type of uterine disease.
  • The obtained results show that perturbation of antioxidant status is more pronounced in blood of patients with premalignant (hyperplastic) and malignant (adenocarcinoma) lesions, compared to those with benign uterine changes such as polypus and myoma.
  • [MeSH-major] Antioxidants / metabolism. Endometrial Hyperplasia / enzymology. Leiomyoma / enzymology. Lipid Peroxidation. Oxidoreductases / blood. Uterine Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / enzymology. Case-Control Studies. Endometrial Neoplasms / blood. Endometrial Neoplasms / enzymology. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Oxidative Stress. Polyps / blood. Polyps / enzymology. Prospective Studies

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657343.001).
  • [ISSN] 0716-9760
  • [Journal-full-title] Biological research
  • [ISO-abbreviation] Biol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antioxidants; EC 1.- / Oxidoreductases
  •  go-up   go-down


86. Liu WX, Hao XS: [Screening, cloning and identification of the human endometrial carcinoma-related genes]. Zhonghua Zhong Liu Za Zhi; 2007 Aug;29(8):584-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Screening, cloning and identification of the human endometrial carcinoma-related genes].
  • OBJECTIVE: To screen, clone and identify the cDNA fragments of human endometrial carcinoma-related genes,and explore the molecular mechanism of endometrial carcinogenesis.
  • METHODS: Pure endometrial glandular epithelial cells and endometrial carcinoma cells were obtained by laser capture microdissection (LCM).
  • RNA from these cells was isolated, and differentially expressed gene fragments that were specialy relevant to endometrial carcingenesis were identified by using fluorescence differential display reverse transcription polymerase chain reaction (FDD-PCR).
  • RESULTS: 38 differential fragments were isolated, 3 of which were expressed more abundantly in normal endometrium and 35 were highly expressed in endometrial carcinoma.
  • CONCLUSION: Gene fragments related to endometrial carcinoma have been obtained by applying LCM and FDD-PCR.
  • To our knowledge it is the first time that the correlation between CDK7, PPP1R12A, CREG, SLC39A10 and endometrial carcinoma is discovered at mRNA level, and their role in molecular mechanism of cancinogenesis is discussed.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Gene Expression Profiling. Genes, Tumor Suppressor. Oncogenes

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18210876.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CREG1 protein, human; 0 / Cation Transport Proteins; 0 / DNA, Complementary; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 0 / SLC39A10 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 2.7.11.22 / cyclin-dependent kinase-activating kinase; EC 3.1.3.53 / Myosin-Light-Chain Phosphatase; EC 3.1.3.53 / PPP1R12A protein, human
  •  go-up   go-down


87. Wang HY, Shen L, Sun Z: [Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures]. Zhonghua Fu Chan Ke Za Zhi; 2006 Apr;41(4):237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures].
  • OBJECTIVE: To evaluate the effectiveness and safety of fertility-sparing treatment with progestins in patients with well-differentiated endometrial adenocarcinoma in women 40 years old or younger.
  • METHODS: Six patients before the age of 40 diagnosed with grade I endometrial adenocarcinoma, who had undergone primary progestin treatment, were retrospectively studied.
  • Relevant articles describing patients with endometrial adenocarcinoma who were treated with hormonal therapy were searched.
  • RESULTS: Four of six cases responded to treatment with normal pathology on follow-up endometrial samplings.
  • CONCLUSIONS: Progestin treatment is proved a safe and feasible therapy in well-differentiated endometrial adenocarcinoma in women 40 years old or younger.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Progestins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16759457.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Progestins
  • [Number-of-references] 22
  •  go-up   go-down


88. Qian J, Weber D, Cochran R, Hossain D, Bostwick DG: Detection of chromosomal anomalies in endometrial atypical hyperplasia and carcinoma by using fluorescence in situ hybridization. Cancer Cytopathol; 2010 Apr 25;118(2):97-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosomal anomalies in endometrial atypical hyperplasia and carcinoma by using fluorescence in situ hybridization.
  • BACKGROUND: Endometrial cancer is the most common pelvic gynecological malignancy.
  • The diagnosis of well-differentiated endometrial adenocarcinoma, atypical hyperplasia, and hyperplasia is often challenging.
  • The authors sought to investigate the utility of chromosomal anomalies for the detection of endometrial hyperplasia and carcinoma using multitarget fluorescence in situ hybridization (FISH).
  • METHODS: Samples were collected by endometrial Tao brush and processed by liquid-based cytological preparation protocol from consecutive cases to include 50 benign, 50 hyperplasia without atypia, 47 atypical hyperplasia, and 53 endometrial cancers.
  • The FISH signals were enumerated in 100 cells per case, and the chromosomal anomalies were correlated with pathologic findings, including histologic diagnoses on matched endometrial tissue samples.
  • RESULTS: Numeric chromosomal anomalies were found in 0% (0 of 50) of benign, 20% (10 of 50) of hyperplasia, 74% (35 of 47) of atypical hyperplasia, and 87% (46 of 53) of carcinoma specimens.
  • The mean percentage of cells with chromosomal changes was 55% in cancer specimens, which was significantly higher than that in hyperplasia without atypia (13%, P < .0001) and atypical hyperplasia (32%, P = .003).
  • FISH anomalies had an overall sensitivity of 81% and specificity of 90% for the detection of atypical hyperplasia and/or endometrial carcinoma.
  • There was no association with grade of endometrial carcinoma.
  • CONCLUSIONS: Multitarget FISH appears to be useful for the differential diagnosis of hyperplasia, atypical hyperplasia, and endometrial adenocarcinoma, with a high level of sensitivity and specificity.
  • It is also a potential tool for the early detection of neoplastic cells in endometrial cytology specimens.
  • Endometrial hyperplasia with FISH-detected chromosomal anomalies may represent a clinically significant subset of cases that warrant close clinical follow-up.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Endometrial Hyperplasia / genetics. Endometrial Neoplasms / genetics. In Situ Hybridization, Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20225199.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI: Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol; 2006 Mar;107(3):701-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These data showed the following rates of pathology: 8.5% low-grade squamous intraepithelial lesions (LSIL), 11.1% high-grade squamous intraepithelial lesions (HSIL), 2.9% adenocarcinoma in situ, 1.4% endometrial hyperplasia, and 5.2% malignancy.
  • The most common malignancies were endometrial adenocarcinoma (57.6%), cervical adenocarcinoma (23.6%), ovarian and fallopian tube carcinoma (6.4%), squamous cell carcinoma of the cervix (5.4%), and other (6.9%).
  • CONCLUSION: Histologic diagnosis showed that 29.0% of these Pap tests had findings requiring follow-up or therapeutic intervention, including a 5.2% rate of malignancy.
  • Based on these findings, 99.6% of the diagnoses are within the region of surveillance when AGUS Pap tests are evaluated with colposcopy and directed biopsy, endocervical curettage, an endometrial biopsy in patients with risk factors for endometrial cancer, and pelvic examination.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Hyperplasia / pathology. Uterine Cervical Neoplasms / pathology


90. Jeong JW, Lee HS, Franco HL, Broaddus RR, Taketo MM, Tsai SY, Lydon JP, DeMayo FJ: beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus. Oncogene; 2009 Jan 08;28(1):31-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus.
  • Endometrioid adenocarcinoma is the most frequent form of endometrial cancer, usually developing in pre- and peri-menopausal women. beta-catenin abnormalities are common in endometrioid type endometrial carcinomas with squamous differentiation.
  • To investigate the role of beta-catenin (Ctnnb1) in uterine development and tumorigenesis, mice were generated which expressed a dominant stabilized beta-catenin or had beta-catenin conditionally ablated in the uterus by crossing the PR(Cre) mouse with the Ctnnb1(f(ex3)/+) mouse or Ctnnb1(f/f) mouse, respectively.
  • Both of the beta-catenin mutant mice have fertility defects and the ability of the uterus to undergo a hormonally induced decidual reaction was lost.
  • Expression of the dominant stabilized beta-catenin, PR(cre/+)Ctnnb1(f(ex3)/+), resulted in endometrial glandular hyperplasia, whereas ablation of beta-catenin, PR(cre/+)Ctnnb1(f/f), induced squamous cell metaplasia in the murine uterus.
  • Therefore, we have demonstrated that correct regulation of beta-catenin is important for uterine function as well as in the regulation of endometrial epithelial differentiation.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Endometrial Hyperplasia / genetics. Endometrium / growth & development. beta Catenin / physiology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Feb 4;397(6718):405-9 [9989404.001]
  • [Cites] Endocrinology. 1999 Jan;140(1):484-91 [9886861.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1442-4 [10197610.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] Int Immunol. 1999 Mar;11(3):317-23 [10221643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] Mol Endocrinol. 1999 Jun;13(6):1005-17 [10379898.001]
  • [Cites] Mol Carcinog. 1999 Jul;25(3):207-18 [10411147.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3346-51 [10416591.001]
  • [Cites] J Reprod Fertil. 1964 Dec;8:331-8 [14248593.001]
  • [Cites] Mol Endocrinol. 2004 Dec;18(12):3035-49 [15358837.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1360-8 [15668893.001]
  • [Cites] Genesis. 2005 Feb;41(2):58-66 [15682389.001]
  • [Cites] Arch Histol Cytol. 2004 Dec;67(5):417-34 [15781983.001]
  • [Cites] Lab Invest. 2005 Jun;85(6):768-79 [15806138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8579-84 [15930138.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):605-19 [16021566.001]
  • [Cites] Dev Biol. 2005 Dec 1;288(1):276-83 [16256976.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):811-6 [16804722.001]
  • [Cites] FEBS Lett. 2006 Oct 16;580(24):5653-60 [17011554.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):269-73 [17224652.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):240-5 [17297296.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1175-86 [17159913.001]
  • [Cites] Dev Biol. 2007 Jul 15;307(2):227-36 [17532316.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(15):5468-78 [17515606.001]
  • [Cites] Trends Endocrinol Metab. 2007 Aug;18(6):234-9 [17588769.001]
  • [Cites] J Histochem Cytochem. 2007 Sep;55(9):963-74 [17533218.001]
  • [Cites] J Biol Chem. 2007 Oct 26;282(43):31725-32 [17711857.001]
  • [Cites] Annu Rev Pathol. 2007;2:57-85 [18039093.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):567-78 [10662781.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):323-6 [10671680.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):209-17 [11161379.001]
  • [Cites] J Pathol. 2001 Jan;193(1):95-101 [11169521.001]
  • [Cites] Development. 2001 Apr;128(8):1253-64 [11262227.001]
  • [Cites] J Pathol. 2001 May;194(1):59-67 [11329142.001]
  • [Cites] Oncogene. 2002 Nov 14;21(52):7981-90 [12439748.001]
  • [Cites] Yonsei Med J. 2002 Dec;43(6):701-11 [12497652.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):577-88 [14742263.001]
  • [Cites] Development. 2004 May;131(9):2061-72 [15073149.001]
  • [Cites] Mol Endocrinol. 2004 May;18(5):1238-50 [14976223.001]
  • [Cites] Biol Reprod. 2004 Aug;71(2):444-54 [15070830.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1260-5 [15492994.001]
  • [Cites] J Endocrinol. 1973 Jan;56(1):133-44 [4683406.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Mol Endocrinol. 1988 Dec;2(12):1243-8 [3216864.001]
  • [Cites] Endocrinology. 1989 Sep;125(3):1683-90 [2667965.001]
  • [Cites] J Biol Chem. 1989 Oct 5;264(28):16941-7 [2674144.001]
  • [Cites] Nature. 1992 Sep 3;359(6390):76-9 [1522892.001]
  • [Cites] Development. 1995 Nov;121(11):3529-37 [8582267.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):143-4 [9326929.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4736-8 [9354433.001]
  • [Cites] Development. 1998 Aug;125(16):3201-11 [9671592.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3526-8 [9721853.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Nature. 1998 Oct 15;395(6703):707-10 [9790192.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3005-10 [9865913.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):55-9 [10076565.001]
  • (PMID = 18806829.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01HD057873; United States / NICHD NIH HHS / HD / U54 HD007495-359009; United States / NICHD NIH HHS / HD / U54 HD007495-359022; United States / NCI NIH HHS / CA / R01 CA077530-09; United States / NICHD NIH HHS / HD / U54 HD007495-350006; United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CA / P50 CA098258-019001; United States / NICHD NIH HHS / HD / U54HD28934; United States / NICHD NIH HHS / HD / R03 HD077495; United States / NCI NIH HHS / CA / P50 CA098258; United States / NICHD NIH HHS / HD / U54 HD028934; United States / NICHD NIH HHS / HD / U54HD0077495; United States / NICHD NIH HHS / HD / R01 HD057873-01; United States / NICHD NIH HHS / HD / R01 HD042311-06A1; United States / NCI NIH HHS / CA / R01 CA077530; United States / NICHD NIH HHS / HD / U54 HD007495; United States / NICHD NIH HHS / HD / R01 HD042311; United States / NICHD NIH HHS / HD / R01HD042311; United States / NCI NIH HHS / CA / P50 CA083639-099005; United States / NCI NIH HHS / CA / R01-CA77530; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA098258-010003; United States / NICHD NIH HHS / HD / R01 HD057873
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, mouse; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS88308; NLM/ PMC2646831
  •  go-up   go-down


91. Baloglu A, Bezircioglu I, Cetinkaya B, Hicyilmaz L: Prospective clinical study of the association between plasma level of free IGF-1 and myometrial invasion min patients with endometrial adenocarcinoma. Ginekol Pol; 2010 Jul;81(7):501-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective clinical study of the association between plasma level of free IGF-1 and myometrial invasion min patients with endometrial adenocarcinoma.
  • INTRODUCTION: Endometrial carcinoma is a common malignancy of the female genital tract.
  • The causal role for Insulin-like growth factor-1 and insulin in endometrial carcinogenesis is well supported and insulin and IGF system have mitogenic and antiapoptotic activity Endometrial cancer cell lines express high-affinity insulin receptors, consistent with there being a direct biological effect of insulin and IGF system on the growth and myometrial invasion of endometrial cancer cells.
  • MATERIAL AND METHODS: Patients with endometrial carcinoma have been divided into three groups: tumor confined to the endometrium (stage IA, n:24), endometrial carcinoma with a minimal invasion (less than 50% of the myometrium; stage IB, n:32), and the control group (n:40).
  • CONCLUSIONS: In the following work we have presented the current understanding of endometrial carcinoma, association between free IGF-1 plasma levels and myometrial invasion in patients with endometrial adenocarcinoma in terms of management and survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Insulin-Like Growth Factor I / analysis. Myometrium / pathology

  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20825050.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


92. Wołuń-Cholewa M, Szymanowski K, Andrusiewicz M, Szczerba A, Warchoł JB: Trichrome Mallory's stain may indicate differential rates of RNA synthesis in eutopic and ectopic endometrium. Folia Histochem Cytobiol; 2010 Jan 1;48(1):148-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichrome Mallory's stain may indicate differential rates of RNA synthesis in eutopic and ectopic endometrium.
  • We have described the differences in the nuclear staining between eutopic and ectopic endometrium as well as endometrial hyperplasia and adenocarcinoma using the Mallory's method.
  • The ultrastructural differences between eutopic and ectopic endometrium have been detected.
  • In normal and hyperplastic endometrium the presence of stromal cell nuclei with an increased affinity to aniline blue has been observed.
  • Similar effects in adenocarcinoma have been noted.
  • The ultrastructural studies have shown that in normal endometrium the stroma contained cells with euchromatic and low electron density cell nuclei.
  • The results indicate that the Mallory's technique may be a useful tool for recognizing the differences between eutopic and ectopic endometrium.
  • The affinity for aniline blue in normal and hyperplastic endometrium occurs most likely due to increased RNA synthesis.
  • Based on Mallory's staining a similarity between hyperplasia and unchanged endometrium in contrast to similar results of the staining obtained in cases of adenocarcinoma and endometriosis may be suggested.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20529831.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Azo Compounds; 0 / trichrome stain; 63231-63-0 / RNA; 82-94-0 / Methyl Green; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


93. Soslow RA: Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol; 2008 Apr;27(2):161-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic subtypes of ovarian carcinoma: an overview.
  • Reproducible subclassification of ovarian carcinomas is biologically and increasingly therapeutically important.
  • The traditional morphologic approach that ignores genotype and immunophenotype is subjective and therefore suboptimal.
  • This review covers the prevalence, morphology, immunophenotype and, in some cases, genotype of each major ovarian cancer subtype.
  • Serous carcinomas, frequently WT1 positive, are morphologically diverse and mimic other tumors.
  • Most transitional cell carcinomas are closely related to them.
  • Mucinous carcinomas are uncommon and should only be diagnosed after extraovarian primaries are excluded; true ovarian mucinous carcinomas are usually low stage.
  • Ovarian endometrioid carcinomas almost always resemble endometrioid carcinomas of endometrium, express estrogen receptors (ER) but not WT1, and are frequently low grade and low stage.
  • Ovarian clear cell carcinomas, negative for ER and WT1 and lacking p53 overexpression, have a limited morphologic repertoire and are frequently low stage at presentation.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / classification. Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Carcinoma / classification. Carcinoma / diagnosis. Carcinoma / pathology. Carcinoma, Transitional Cell / classification. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Diagnosis, Differential. Female. Humans. Neoplasms, Cystic, Mucinous, and Serous / classification. Neoplasms, Cystic, Mucinous, and Serous / diagnosis. Neoplasms, Cystic, Mucinous, and Serous / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317227.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 124
  •  go-up   go-down


94. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res; 2005 Sep 15;11(18):6422-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
  • PURPOSE: The presence of similar histologic subtypes of epithelial ovarian and endometrial cancers has long been noted, although the relevance of this finding to pathogenesis and clinical management is unclear.
  • Despite similar clinical characteristics, histologic subtypes of cancers of the ovary and endometrium are treated according to organ of origin.
  • This study compares the gene expression profiles of analogous histologic subtypes of cancers of the ovary and endometrium using the same genomic platform to determine the similarities and differences between these tumors.
  • EXPERIMENTAL DESIGN: Gene expression profiles of 75 cancers (endometrioid, serous, and clear cell) of the ovary and endometrium, five renal clear cell cancers, and seven normal epithelial brushings were determined using a 11,000-element cDNA array.
  • RESULTS: Comparison across endometrial and ovarian cancers and serous and endometrioid tumors showed expression patterns reflecting their organ of origin.
  • A set of 43 genes was common to comparisons of each of the three histologic subtypes of ovarian cancer with normal ovarian surface epithelium.
  • CONCLUSIONS: The comparison of the gene expression profiles of endometrioid and serous subtypes of ovarian and endometrial cancer are largely unique to the combination of a particular subtype in a specific organ.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Carcinoma, Endometrioid / genetics. Cystadenocarcinoma, Serous / genetics. Endometrial Neoplasms / genetics. Gene Expression Profiling. Ovarian Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Cluster Analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kidney Neoplasms / genetics. Kidney Neoplasms / metabolism. Oligonucleotide Array Sequence Analysis / methods. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166416.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


95. Lou HY, Lin kQ, Ye DF, Xie X, Yu X: [Possibility of PTEN expression on predicting pathologic risk factors of endometrioid adenocarcinoma before operation]. Ai Zheng; 2005 Jun;24(6):748-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Possibility of PTEN expression on predicting pathologic risk factors of endometrioid adenocarcinoma before operation].
  • BACKGROUND & OBJECTIVE: Fully estimating pathologic risk factors is important for selecting operation and predicting prognosis for endometrioid adenocarcinoma.
  • Phosphatase and tension homology deleted on chromosome ten (PTEN), taken as the housekeeping gene of endometrium, has the highest mutation rate in endometrioid adenocarcinoma.
  • This study was to investigate the effect of PTEN on predicting pathologic risk factors of endometrioid adenocarcinoma before operation.
  • METHODS: Clinicopathologic data of 107 patients with endometrioid adenocarcinoma were retrospectively analyzed.
  • RESULTS: Deletion rate of PTEN was 56.1% in the 107 endometrioid adenocarcinoma patients.
  • CONCLUSION: Detection of PTEN can't predict the high risk factors of endometrioid adenocarcinoma before operation.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. PTEN Phosphohydrolase / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946494.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


96. Ackerman I: Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument. Int J Gynecol Cancer; 2010 Oct;20(11 Suppl 2):S67-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument.
  • Adjuvant external beam pelvic radiation therapy for stage I endometrial cancer has become increasingly confusing and controversial.
  • By using evidence from the literature, including the most recent randomized data, an argument is made for the use of external beam pelvic radiotherapy for a 63-year-old woman who has undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a grade 2 endometrioid adenocarcinoma of the uterus with 9 of 12 mm of invasion and the presence of lymphovascular space involvement.
  • [MeSH-major] Carcinoma, Endometrioid / prevention & control. Carcinoma, Endometrioid / radiotherapy. Endometrial Neoplasms / prevention & control. Endometrial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053530.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


97. Chialina SG, Fornes C, Landi C, de la Vega Elena CD, Nicolorich MV, Dourisboure RJ, Solano A, Solis EA: Microsatellite instability analysis in hereditary non-polyposis colon cancer using the Bethesda consensus panel of microsatellite markers in the absence of proband normal tissue. BMC Med Genet; 2006;7:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability analysis in hereditary non-polyposis colon cancer using the Bethesda consensus panel of microsatellite markers in the absence of proband normal tissue.
  • BACKGROUND: Hereditary non-polyposis colon cancer (HNPCC) is an autosomal dominant syndrome predisposing to the early development of various cancers including those of colon, rectum, endometrium, ovarium, small bowel, stomach and urinary tract.
  • In this study, we report the analysis for genetic counseling of three first-degree relatives (the mother and two sisters) of a male who died of colorectal adenocarcinoma at the age of 23.
  • METHODS: Tumor MSI testing is described as initial screening in both primary and metastasis tumor tissue blocks, using the reference panel of 5 microsatellite markers standardized by the National Cancer Institute (NCI) for the screening of HNPCC (BAT-25, BAT-26, D2S123, D5S346 and D17S250).
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. DNA Mutational Analysis / methods. Germ-Line Mutation. Microsatellite Repeats. MutS Homolog 2 Protein / genetics

  • Genetic Alliance. consumer health - Hereditary Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Medicina (B Aires). 2000;60(2):188-94 [10962807.001]
  • [Cites] Curr Biol. 1999 Aug 26;9(16):907-10 [10469597.001]
  • [Cites] Ann Genet. 2002 Apr-Jun;45(2):71-5 [12119215.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Cancer Treat Rev. 2003 Dec;29(6):461-70 [14585257.001]
  • [Cites] J Exp Med. 1988 Jan 1;167(1):225-30 [2826637.001]
  • [Cites] Dis Colon Rectum. 1991 May;34(5):424-5 [2022152.001]
  • [Cites] Gastroenterology. 1993 May;104(5):1535-49 [8482467.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1215-25 [8261515.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1146-58 [9322509.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):349-53 [10433928.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4545-9 [11389088.001]
  • (PMID = 16426447.001).
  • [ISSN] 1471-2350
  • [Journal-full-title] BMC medical genetics
  • [ISO-abbreviation] BMC Med. Genet.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ PMC1373649
  •  go-up   go-down


98. Gurgan T, Bozdag G, Demirol A, Ayhan A: Preserving fertility before assisted reproduction in women with endometrial carcinoma: case report and literature review. Reprod Biomed Online; 2007 Nov;15(5):561-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preserving fertility before assisted reproduction in women with endometrial carcinoma: case report and literature review.
  • Fertility-preserving treatment with progestin may be considered in nulliparous women with well-differentiated endometrial carcinoma.
  • Owing to persistent menstrual irregularity and thick endometrium, a diagnostic office hysteroscopy with endometrial biopsy was performed and revealed a well-differentiated adenocarcinoma.
  • Although the woman wished to retain her childbearing potential with conservative management followed by an assisted reproduction cycle, the repeated endometrial biopsies during progestin treatment revealed persistent adenocarcinoma.
  • Complementary surgery was performed due to persistent endometrial malignancy, which noted well-differentiated endometrioid adenocarcinoma without myometrial invasion or extrauterine disease.
  • A review of cases with endometrial carcinoma that have been treated with conservative management and a subsequent assisted cycle is also presented here.
  • Therefore, patient and physician should always consider carefully if fertility-preserving management is preferred after diagnosis of endometrial carcinoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Fertility. Megestrol Acetate / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028748.001).
  • [ISSN] 1472-6483
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; TJ2M0FR8ES / Megestrol Acetate
  • [Number-of-references] 19
  •  go-up   go-down


99. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, Shim JU, Mok JE, Kim TJ: Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer; 2009 Aug;19(6):1068-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
  • INTRODUCTION: The purpose of this study was to evaluate the efficacy of conservative treatment with progestin and pregnancy outcomes in women with early-stage endometrial cancer.
  • METHODS: We retrospectively analyzed the medical records of 35 patients with endometrial adenocarcinoma, who were treated with progestin from January 1996 to December 2006.
  • Women with early-stage grade 1 endometrioid endometrial adenocarcinoma, who wanted to receive conservative treatment or preserve fertility, were included.
  • Complete remission (CR) was defined as no evidence of endometrial adenocarcinoma or hyperplasia.
  • Partial remission was diagnosed when the patient developed endometrial hyperplasia, and persistent disease was defined as residual endometrial adenocarcinoma by pathologic confirmation.
  • CONCLUSIONS: Conservative treatment with progestin can be considered a good therapeutic option in patients with well-differentiated early-stage endometrioid endometrial adenocarcinoma who wish to preserve their uteri or become pregnant.
  • [MeSH-major] Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / rehabilitation. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / rehabilitation. Pregnancy Outcome. Progestins / therapeutic use

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820370.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Progestins; C2QI4IOI2G / Medroxyprogesterone Acetate; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


100. Papanas N, Giatromanolaki A, Galazios G, Maltezos E, Sivridis E: Endometrial carcinoma and diabetes revisited. Eur J Gynaecol Oncol; 2006;27(5):505-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma and diabetes revisited.
  • OBJECTIVE: To investigate whether endometrial adenocarcinomas are intrinsically different in diabetic as compared to non-diabetic patients.
  • METHODS: A series of 208 patients with histologically confirmed endometrial adenocarcinomas were divided into groups of diabetic (n = 63) and non-diabetic (n = 145) patients.
  • RESULTS: A history of a second neoplasia was significantly more frequent in diabetic than in non-diabetic patients (p = 0.001), but other endometrial cancer associated characteristics, such as tumor morphology, FIGO stage, obesity, hypertension, nulliparity, estrogen use and menopausal status did not differ between the groups.
  • CONCLUSIONS: A second neoplasia occurred significantly more frequently in diabetic than in non-diabetic patients with endometrial carcinoma, but long-term survival and other clinical and histological features were the same in the two groups.
  • These results indicate that endometrial adenocarcinoma is not intrinsically different in diabetic patients.
  • [MeSH-major] Adenocarcinoma / complications. Diabetes Complications. Endometrial Neoplasms / complications. Neoplasms, Second Primary / epidemiology

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139988.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement